

2-1-2018

Beyond the Matrix: The Many Non-ECM Ligands for Integrins

Bryce LaFoya
Boise State University

Jordan A. Munroe
Boise State University

Alison Miyamoto
California State University

Michael A. Detweiler
Boise State University

Jacob J. Crow
Boise State University

See next page for additional authors

Authors

Bryce LaFoya, Jordan A. Munroe, Alison Miyamoto, Michael A. Detweiler, Jacob J. Crow, Tana Gazdik, and Allan R. Albig



Review

Beyond the Matrix: The Many Non-ECM Ligands for Integrins

Bryce LaFoya¹, Jordan A. Munroe², Alison Miyamoto³, Michael A. Detweiler², Jacob J. Crow¹, Tana Gazdik² and Allan R. Albig^{1,2,*}

¹ Biomolecular Sciences PhD Program, Boise State University, Boise, ID 83725, USA; brycelafoya@u.boisestate.edu (B.L.); jacobcrow@u.boisestate.edu (J.J.C.)

² Department of Biological Sciences, Boise State University, Boise, ID 83725, USA; jordanmunroe@u.boisestate.edu (J.A.M.); mikedetweiler@u.boisestate.edu (M.A.D.); tanagazdik@u.boisestate.edu (T.G.)

³ Department of Biological Science, California State University, Fullerton, CA 92831, USA; almiyamoto@fullerton.edu

* Correspondence: AllanAlbig@boisestate.edu; Tel.: +1-208-426-1541

Received: 31 December 2017; Accepted: 30 January 2018; Published: 2 February 2018

Abstract: The traditional view of integrins portrays these highly conserved cell surface receptors as mediators of cellular attachment to the extracellular matrix (ECM), and to a lesser degree, as coordinators of leukocyte adhesion to the endothelium. These canonical activities are indispensable; however, there is also a wide variety of integrin functions mediated by non-ECM ligands that transcend the traditional roles of integrins. Some of these unorthodox roles involve cell-cell interactions and are engaged to support immune functions such as leukocyte transmigration, recognition of opsonization factors, and stimulation of neutrophil extracellular traps. Other cell-cell interactions mediated by integrins include hematopoietic stem cell and tumor cell homing to target tissues. Integrins also serve as cell-surface receptors for various growth factors, hormones, and small molecules. Interestingly, integrins have also been exploited by a wide variety of organisms including viruses and bacteria to support infectious activities such as cellular adhesion and/or cellular internalization. Additionally, the disruption of integrin function through the use of soluble integrin ligands is a common strategy adopted by several parasites in order to inhibit blood clotting during hematophagy, or by venomous snakes to kill prey. In this review, we strive to go beyond the matrix and summarize non-ECM ligands that interact with integrins in order to highlight these non-traditional functions of integrins.

Keywords: integrin; extracellular matrix; counterreceptor; disintegrin; immune system; stem cell; pathogen; virus; bacteria; venom; growth factor; hormone

1. Introduction

The adhesion of cells to extracellular matrices is a fundamental requirement for multicellular organisms, and animals employ many mechanisms to fulfill this demand. Amongst these mechanisms of adhesion, integrins are perhaps the most ubiquitous. Integrins are heterodimeric transmembrane proteins, made up of non-covalently paired α and β subunits, which serve as adhesion and signaling hubs at the cell surface. In mammals, there are 18 α -integrin subunits and eight β -integrin subunits that can combine to form as many as 24 unique heterodimeric receptor complexes [1]. Typically, ligand binding is carried out through integrin receptor recognition of small peptide sequences. Target sequences for integrins can be as simple as the RGD or LDV tripeptides, or more complex as in the case of the GFOGER peptide [1]. Many classical extracellular matrix (ECM) proteins contain these short integrin recognition motifs. RGD sequences are found in both vitronectin and fibronectin,

an LDV motif is present in fibronectin, GFOGER is found within collagen, and the target sequence within laminin has not yet been defined [1]. These sequences are not globally recognized by all integrins; therefore, integrin heterodimers are often grouped by the target sequences they specialize in recognizing (Figure 1). Once bound to its ligand, an integrin not only provides adhesion, but also initiates signaling mechanisms which allow cells to respond to the mechanical and chemical properties of the cellular microenvironment. The primary signaling mediators working downstream of integrins include focal adhesion kinase (FAK), Src-family protein tyrosine kinases, and integrin-linked kinase (ILK) [2]. Upon adhesion, cytoskeletal proteins are recruited to the cytoplasmic tails of integrins, forming a linkage between the ECM and cytoskeleton [2].




Figure 1. Integrin heterodimers and their ligands. Integrins are heterodimeric cell surface receptors that bind extracellular matrix (ECM) molecules. In addition to this role, integrins also bind many non-ECM ligands. Integrin subunits connected by a ray represent heterodimeric α/β binding partners. The inner ring depicts integrin heterodimers grouped into families based upon their classical binding profile. These families include RGD receptors, collagen (GFOGER) receptors, laminin receptors, or leukocyte-specific receptors. Within the outer ring, the non-ECM ligands of these families are listed. Non-ECM ligands include growth factors, hormones, venomous compounds, disintegrins, bacterial proteins, fungal polysaccharides, viruses, polyphenols, and counterreceptors.

As a family of proteins, integrins and many of their downstream signaling intermediates have a long evolutionary history. Beginning at the root of the metazoan lineage, sponges have been shown to express α - and β -integrin subunits [3,4] that bind to peptides in a fashion similar to mammalian integrins [5]. Interestingly, integrin-encoding genes have been found in the single-celled eukaryotic

relatives of metazoans, thus the origin of integrins predates the emergence of metazoans [6]. Moreover, components of integrin signaling machinery such as FAK, Src, and ILK, and integrin-interacting cytoskeletal proteins such as α -actinin, talin, vinculin, and paxillin, have pre-metazoan origins [6]. This suggests that integrins and their aforementioned signaling machinery may have played an important role in the evolution of multicellularity.

Beyond their traditional role as mediators of ECM attachment, a vast literature has developed that describes interactions between integrins and ligands that are not located in the classical extracellular matrix. For example, integrins have been shown to interact with various proteins on the surfaces of eukaryotic, prokaryotic, and fungal cells, as well as a range of viruses. Within eukaryotes specifically, integrin-mediated cell-cell adhesion has been shown to coordinate a range of interactions and processes including leukocyte extravasation, stem cell homing, tumor cell migration, erythrocyte development, and interactions in the immune system. For infectious prokaryotes, integrins are exploited as cell surface adhesion receptors that mediate colonization and/or the bypassing of epithelial or endothelial barriers. Beyond mediating cellular interactions, integrins can also serve as cell surface receptors for hormones, growth factors, and polyphenols. Finally, integrins are also common targets for a class of small molecules called disintegrins, which are components of various snake venoms, and are also employed by hematophagous parasites. Collectively, the range of non-ECM molecules that interact with integrins is vast, making integrins indispensable mediators of cell biology at large. The goal of this review is to highlight some of the best understood non-ECM ligands of integrins and discuss the diverse biological roles for these interactions.

2. Integrin-Mediated Cell-Cell Interactions

The first integrins discovered were isolated based on their ability to bind to fibronectin, which had itself just recently been identified (reviewed in [7]). However, in the early days of integrin research, several groups studying cell-cell adhesion in the immune system were also on the forefront of integrin identification (reviewed in [8,9]). In fact, integrins that mediate cell-cell adhesion in the immune system were among the first integrins to be characterized [8]. As more integrins were discovered, it became apparent that the majority of integrins established cell-ECM connections rather than cell-cell connections. Nonetheless, it is important to understand that integrins are important mediators of cell-cell adhesion. The term counterreceptor has often been used to describe membrane-bound, non-matrix integrin ligands which facilitate cell-cell contact and will be used to differentiate them from the other non-matrix ligands in this review. While there are many types of counterreceptors, the best-known examples include the immunoglobulin superfamily cell adhesion molecules (IgCAMs) and junctional adhesion molecules (JAMs). Collectively, interactions between integrins and these counterreceptors mediate a range of immune cell functions including leukocyte extravasation from the blood stream, immunological surveillance in the gut, and hematopoietic stem cell homing and mobilization. Additionally, non-ECM ligands enhance the interaction between pathogens and phagocytic immune cells, acting as phagocytic primers and inducers of neutrophil extracellular traps. Beyond the immune system, non-ECM-based integrin interactions are important during the transmigration and metastasis of tumor cells, and during erythrocyte development. Integrins and the non-ECM ligands that mediate these cell-cell interactions are listed in Table 1.

Table 1. Selected non-ECM ligands which mediate cell-cell interactions.

Integrin Dimers		Common Name	Non-ECM Ligand	Function of Interaction [Key Refs]
$\alpha 4\beta 1$	VLA-4	Very late antigen-4	MAdCAM1 VCAM1 AM-B	Leukocyte adhesion [10–12] Leukocyte adhesion [10–12] Erythrocyte differentiation [13–15] Cancer cell metastasis [16] Leukocyte transmigration [11]
$\alpha 4\beta 7$	LPAM	Lymphocyte Peyer’s patch adhesion molecule	MAdCAM1	T-lymphocyte homing [17] HSC homing to bone marrow [18]
$\alpha 5\beta 1$	Fibronectin receptor	Fibronectin receptor	Glycoprotein NMB	Cancer cell growth, metastasis [19]
$\alpha E\beta 7$			E-cadherin	Cytotoxic T cell targeting of tumor cells [20]
$\alpha L\beta 2$	LFA-1	Lymphocyte function associated antigen-1	ICAM1, 2, 3 JAM-A	Leukocyte adhesion [10,11] Leukocyte transmigration [11]
$\alpha M\beta 2$	Mac-1/CR3	Macrophage antigen-1/Complement receptor-3	ICAM1 β -glucan Complement C3 LL-37 JAM-C HMGB1	Leukocyte adhesion [10,11] NETosis [21,22] Phagocytosis [23,24] Bacterial opsonization [25–29] Leukocyte transmigration [11] NETosis [30]
$\alpha V\beta 3$	Vitronectin receptor	Vitronectin receptor	L1CAM	Cancer cell metastasis [31,32]
$\alpha X\beta 2$	CR4/CD11c/CD18	Complement receptor-4	Complement C3	Phagocytosis [23,24]

mucosal addressin cell adhesion molecule (MAdCAM), vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), junctional adhesion molecule (JAM), glycoprotein non-metastatic gene B (Glycoprotein NMB), high mobility group box protein (HMGB), L1 cell adhesion molecule (L1CAM), hematopoietic stem cell (HSC), neutrophil extracellular trap (NET).

2.1. Integrin-Counterreceptor Interactions in Leukocyte Extravasation

Integrin-counterreceptor interactions play multiple roles during extravasation, a process in which white blood cells are recruited from the blood stream to a site of inflammation (depicted in Figure 2). Extravasation begins when glycoproteins on the leukocyte cell surface, such as P-selectin glycoprotein ligand-1 (PSGL-1), bind endothelial selectins, which allows the leukocyte to slow down as it rolls along the vessel wall [33]. Next, local chemokines stimulate leukocyte integrins to adopt a high-affinity state, causing them to bind specific immunoglobulin superfamily cell adhesion molecules (IgCAMs) on endothelial cells [34]. There are many integrin-IgCAM pairs involved in this process: α L β 2 (LFA-1) integrin binds to ICAM1, 2, or 3, α M β 2 (Mac-1) integrin binds to ICAM1, and α 4 β 1 (VLA-4) integrin binds to VCAM1 or MAdCAM1 (reviewed in [10]). Additionally, leukocyte integrins can bind a family of proteins known as junctional adhesion molecules (JAMs) found on endothelial cells. Similar to integrin-IgCAM interactions, integrins display specificity for particular JAM proteins: JAM-A binds to α L β 2, JAM-B binds to α 4 β 1, and JAM-C binds to α M β 2 [11]. All of these integrin-counterreceptor binding events serve to tightly adhere the leukocyte to the endothelium, enabling the white blood cell to cross the endothelial layer (a process known as transendothelial migration) in order to reach the inflamed tissue.

2.2. Non-ECM Integrin Ligands as Primers for Phagocytosis

One of the best-characterized examples of non-ECM integrin-binding ligands in the immune system involves the interplay of integrins with the complement system. Complement proteins aid in the immune system's clearance of pathogens by attaching to invaders and tagging them for destruction. Integrin β 2 is essential for complement recognition by the complement receptors α M β 2 (Mac-1, CR3) and α X β 2 (CR4) integrins [23]. α M β 2 and α X β 2 ligation with the iC3b component of complement induces the phagocytosis of complement opsonized pathogens and particles by phagocytic immune cells (depicted in Figure 2) [24]. Despite high homology between both integrins, they bind the iC3b fragment of complement via distinctive receptor sites, which may afford a greater diversity of leukocytes in opsonized target recognition modes [35]. This leads to the intriguing possibility of cooperativity between two integrins binding the same complement molecule [35].

Phagocytosis mediated by integrins is not strictly complement dependent. Human cathelicidin peptide LL-37, an antimicrobial peptide that binds to the prokaryotic cell wall, inserts itself into the membrane, and enhances phagocytosis by interacting with α M β 2 integrin present on neutrophils and macrophages [26,27]. As an important part of innate defenses, LL-37 is expressed in various mammalian tissues and released upon contact with bacterial invaders [29]. For example, upon infection by *Helicobacter pylori*, gastric epithelial cells express and secrete LL-37, thus tagging the bacterial invaders for destruction by phagocytic immune cells (depicted in Figure 2) [28]. Interestingly, LL-37 binds α M β 2 with a comparable strength to complement C3d, a ligand with one of the strongest known affinities for α M β 2 [25].




Figure 2. Integrins act as “double agents” during *Helicobacter pylori* infection in the stomach, serving to potentiate bacterial pathogenicity while also aiding in the immune response. *H. pylori* bacteria in the gastric lumen bind integrins on gastric epithelial cells in order to inject the virulence factor CagA. As shown in the magnified view of this process, docking of $\alpha 5\beta 1$ integrin is achieved through integrin affinity for the RGD motif of the CagL protein component of the type IV secretion system (T4SS). Integrin $\alpha 5\beta 1$ -mediated stabilization of the T4SS facilitates the translocation of CagA while activating intracellular kinases. Once in the cytosol, CagA is phosphorylated by Src family kinases (SFKs) and Abelson (ABL) kinases, which potentiates its virulence. Phospho-CagA activates Src homology 2 domain-containing phosphatase-2 (SHP-2) and mitogen-activated protein kinase (MAPK) signaling, triggering cytoskeletal remodeling. CagA disrupts cell-cell junctions, activates the nuclear factor- κ B (NF- κ B) pathway, and stimulates cytokine production. Alternatively, CagL docking with $\alpha V\beta 5$ integrin on gastric G cells activates integrin-linked kinase (ILK), which stimulates epidermal growth factor receptor (EGFR) and MAPK activation, inducing gastrin production. These mechanisms increase the permeability of the gastric epithelium, which aids *H. pylori* dissemination into the underlying lamina propria. This stimulates an inflammatory response causing the release of the antimicrobial peptide LL-37 from gastric epithelial cells and recruitment of immune cells from the blood stream. As shown in the magnified view of the recruitment process, leukocytes first stick to inflamed endothelium through selectin binding, which facilitates integrin-mediated tight adhesion. This leads to leukocyte extravasation into the lamina propria, where neutrophils and macrophages phagocytize bacteria. Phagocytosis is mediated through integrin recognition of the opsonization factors LL-37 and complement. Neutrophil extracellular traps (NETs) are stimulated through integrin interaction with pathogens.

2.3. Non-ECM Integrin Ligands as Triggers for NETosis

Another example of non-ECM integrin ligation at work in the innate immune system is the neutrophil extracellular trap (NET). In the process of NETosis, chromatin is ejected from neutrophils upon interaction with pathogens, thus entangling foreign invaders in a web of DNA and histones (depicted in Figure 2) [36]. This process is mediated through pathogen recognition by neutrophil integrins. For example, the pathogen-associated molecular pattern, β -glucan, found on *Candida albicans* is recognized by $\alpha M\beta 2$ at a unique lectin-like domain, and its binding stimulates NETosis [21]. Once stimulated, anti-microbial peptides are integrated into NETs. These include defensins and the $\alpha M\beta 2$ ligand LL-37 [22]. NETosis is not exclusively used to trap foreign invaders, as it is also involved

in wound healing and sterile inflammation [37]. For instance, during cell necrosis the chromatin protein high-mobility group box 1 (HMGB1 aka amphoterin) is released extracellularly and recruits neutrophils by binding integrin $\beta 2$ [38]. HMGB1 has been demonstrated to be an inducer of NETosis when presented on platelets during thrombosis [30]. This evidence suggests that HMGB1 serves as a molecule that is capable of signaling to white blood cells the presence of tissue damage through leukocyte integrins. Although $\alpha M\beta 2$ plays a starring role in the literature connecting NETosis and integrins, other integrins may be involved. Bacterial invasin proteins from *Yersinia pseudotuberculosis* interact with neutrophil integrin $\beta 1$, stimulating phagocytosis while also causing the release of NETs [39]. In addition to trapping cells within a tangle of DNA and histones, fibronectin has been identified in NETs, which ligates to $\alpha V\beta 3$ and $\alpha 5\beta 1$ integrins found on neutrophils and cancer cells, thus potentially enhancing cancer cell-leukocyte interaction [40]. Collectively, this information demonstrates rich evidence for the importance of integrin engagement during NETosis.

2.4. Non-ECM Integrin Ligands in Immune Surveillance

The intestinal immune system must display tolerance towards commensal microbiota and food antigens while still maintaining immunogenicity against pathogens. In the gut mucosa, resident antigen-presenting cells (APCs) have the job of sampling foreign antigens. APCs then transport these antigens to specialized gut-associated lymphoid tissue where they can interact with naïve T cells to promote their maturation. Additionally, the APCs imprint intestinal homing properties on the T cells through inducing the expression of $\alpha 4\beta 7$ integrin and C-C chemokine receptor type 9, a receptor for the gut-associated C-C motif chemokine 25 (CCL25) [41]. Mature T effector cells then reenter the circulation and can be recruited back to the gastrointestinal tract during times of inflammation through gut endothelial expression of CCL25 and the $\alpha 4\beta 7$ counterreceptor, MAdCAM1 [17]. There is also a role for $\alpha 4\beta 1$ -VCAM1 interactions in the gut; this pair mediates the binding of effector T cells to inflamed gut epithelium [12].

Integrins in the gut also bind to cadherins to modulate the immune response. For instance, cadherin 26 binding to integrins αE and $\alpha 4$ can lead to a T cell immunosuppression phenotype [42]. Moreover, this study found that a similar phenotype is provoked through the treatment of T cells with a soluble form of cadherin 26. So, unlike the integrin-mediated IgCAM interactions in the gut, cadherin binding appears to moderate the immune response. It has been suggested that this interaction may therefore be involved in resolving inflammation [42]. Cadherin-integrin interactions in the lungs have been shown to mediate the engagement of cytotoxic T lymphocytes (CTLs) with cancer cells. Here, CTLs employ $\alpha E\beta 7$ integrin to engage E-cadherin on cancer cell surfaces in order to facilitate accurate targeting and release of cytotoxic granules [20].

2.5. Integrin-Mediated Stem Cell Homing

The homing and mobilization of hematopoietic stem cells (HSCs) to and from the bone marrow is also regulated by integrins (reviewed in [13]). After the treatment of hematologic malignancies with large doses of radiation and/or chemotherapy, transplantation of HSCs is commonly performed. Success of the HSC engraftment within the bone marrow is dependent upon proper HSC homing to a bone marrow niche where they can regenerate hematopoietic lineages. New evidence is revealing that integrin engagement of counterreceptors plays a critical role in this homing process. For example, Murakami et al. determined that a subpopulation of murine HSCs expressing integrin $\beta 7$ have enhanced homing capabilities to bone marrow niches compared to their counterparts which do not express $\beta 7$ [18]. Mechanistic insight was provided when it was revealed that $\alpha 4\beta 7$ integrins on HSCs were binding MAdCAM1 present on endothelial cells within the bone marrow niche, and $\beta 7$ knockout HSCs showed decreased CXCR4 homing receptor expression [18].

In addition to $\alpha 4\beta 7$ -MAdCAM1 interactions, $\alpha 4\beta 1$ -VCAM1 binding also mediates HSC retention in bone marrow niches. The importance of $\alpha 4$ integrin to this interaction is supported by the phenotypes of multiple $\alpha 4$ knockout mouse models that show elevated numbers of HSCs in the

bloodstream relative to wild-type littermates (reviewed in [13]). The treatment of mice with Bortezomib, which inhibits the expression of VCAM1, also increases HSC mobilization [14]. Together, these results support a role for integrins in holding HSCs within the bone marrow and have raised great clinical interest in using Bortezomib-induced mobilization for the harvesting of HSCs from the peripheral blood of healthy individuals for use in transplantation.

Another integrin-targeting small molecule antagonist is the drug Finategrast; it inhibits $\alpha 4\beta 1$ and $\alpha 4\beta 7$ activity and can also be used to mobilize HSCs from the bone marrow to the circulation, making HSC harvesting much less invasive. There is particular interest in using Finategrast for in utero hematopoietic cell transplants (IUHCT). These transplants can be especially useful for diseases where a more mature immune system can thwart the therapeutic benefit of the transplanted cells (reviewed in [43]). Finategrast was tested in a mouse model of IUHCT and found to increase long-term engraftment of HSCs; there was 15% engraftment at six months with Finategrast, compared to 3% with vehicle alone [44]. The current thinking is that the mobilization of endogenous HSCs through the disruption of integrin adhesion by Finategrast makes room in the bone marrow for transplanted HSCs to compete with endogenous cells for niche binding. Although still in preclinical studies, Finategrast is well-tolerated by adults but has not yet been tested in children (reviewed in [43]).

Some interesting new data on mesenchymal stem cell (MSC) homing demonstrates that the role of integrin αL (CD11a) in MSC transmigration across vessel endothelium differs from that of leukocyte extravasation [45]. Using zebrafish whose endothelium was labeled with green fluorescent protein as a model system, mammalian leukocytes, cardiac stem cells, and MSCs were transplanted to determine their transmigration properties. As expected, leukocyte extravasation proceeded in an αL -dependent fashion, as αL -blocking antibodies inhibited leukocyte extravasation. However, the blocking antibodies did not inhibit the transmigration of cardiac stem cells or MSCs, indicating that these cells were traversing the endothelium in an αL -independent fashion that was found to rely on the remodeling of the endothelium for vascular expulsion of these types of stem cells. Based on this evidence and additional phenotypic differences in the transmigration of cardiac stem cells and MSCs, the authors have named this alternate process angiopellosis [45].

2.6. Integrin-Counterreceptor Interactions in Tumor Cell Migration

Integrin binding to IgCAMs also mediates tumor cell binding to endothelial cells, influencing metastasis. Many of these interactions involve L1CAM (reviewed in [46]); this protein contains an RGD motif that binds to $\alpha V\beta 3$ integrin [47,48]. The expression of L1CAM by various types of cancer cells is utilized to engage $\alpha V\beta 3$ on endothelial cells. It has been demonstrated that L1CAM expression in glioma tumor cells serves to promote the motility of both cancer cells [31] and endothelial cells [32], thus having important implications for both metastasis and angiogenesis, respectively. Other non-ECM integrin ligands have been implicated in tumor cell migration. For example, when expressed on cancer cells, VCAM1 has been identified as a driver of metastasis due to its ability to bind $\alpha 4\beta 1$ integrin expressed on lymph node endothelium (reviewed in [16]). Additionally, metastatic breast cancer cells express the transmembrane glycoprotein NMB that contains an RGD motif and can bind to $\alpha 5\beta 1$ integrin on adjacent tumor cells. This interaction activates Src and FAK signaling within the tumor and leads to increased growth and metastasis [19].

2.7. Integrin-Counterreceptor Interactions in Erythrocyte Development

Since integrins can bind to both ECM and other cells, it is perhaps not surprising that there are modulators that can push integrins towards either a cell-ECM or a cell-cell interaction. During erythrocyte differentiation in the bone marrow, immature erythroblasts cluster around a central macrophage, forming what is known as erythroblastic islands. This cell-cell interaction is mediated by $\alpha 4\beta 1$ on erythroblasts and VCAM1 on macrophages and is an essential part of the maturation process [15]. The same $\alpha 4\beta 1$ integrin can bind to fibronectin in the ECM, and the modulation of $\alpha 4\beta 1$ binding to either macrophages or ECM is in part due to the activity of erythrocyte tetraspanin

proteins CD81, CD82, and CD151 [49]. These tetraspanins are co-expressed with $\alpha 4\beta 1$ on human proerythroblasts, where they increase the affinity and/or clustering of integrins to favor $\alpha 4\beta 1$ -VCAM1 interactions over $\alpha 4\beta 1$ -fibronectin interactions [49].

3. Non-ECM Integrin Ligands of Viruses

Although there is debate as to when viruses first emerged in the evolution of life, it is likely that viruses (in one form or another) have co-existed with cells for nearly as long as cells have existed [50]. It is also safe to assume that viruses have a long history of exploiting cell surface receptors to facilitate their infectious cycles. As already discussed, integrins are first present in evolutionary history at the root of the metazoan lineage, and perhaps predate metazoans [3,4,6]. Therefore, it is not surprising that many species of viruses have exploited (and continue to exploit) integrins as a major point of cell attachment, entry, and eventually infection of target cells. A common theme among many of the viruses discussed here is the display of RGD motifs on viral capsids to bind to integrins that are commonly found on either epithelial or endothelial surfaces [51,52]. Presumably, the RGD motif serving as a minimal integrin-binding unit accommodates the viral quest for genomic minimization. Additionally, RGD-recognizing integrins are common in tissues targeted by invading viruses. However, RGD-based mechanisms are not the only means of integrin engagement by viruses, as some viruses employ other integrin targeting motifs. The virus-integrin interactions we have chosen to highlight are in no way an exhaustive list (for a more comprehensive review of the subject, refer to [53,54]). Integrins that participate in viral interactions that we discuss are listed in Table 2 and depicted in Figure 3.

Table 2. Selected integrin binding by viruses.

Integrin	Virus Name [Key Refs]
$\alpha 1\beta 1$	Ross River virus [55]
$\alpha 2\beta 1$	Echovirus 1 [56,57] Cytomegalovirus [58] Rotavirus [59,60]
$\alpha 3\beta 1$	Kaposi's sarcoma-associated herpesvirus [61] Adenovirus [62]
$\alpha 4\beta 1$	Infectious bursal disease virus [63] Rotavirus [60]
$\alpha 5\beta 1$	Foot-and-mouth disease virus [64] Epstein-Barr virus [65] Adenovirus [66]
$\alpha 6\beta 1$	Cytomegalovirus [58]
$\alpha 9\beta 1$	Kaposi's sarcoma-associated herpesvirus [67]
$\alpha M\beta 2$	Adenovirus [68]
$\alpha V\beta 1$	Echovirus 22 [69,70] Adenovirus [71]
$\alpha V\beta 3$	Echovirus 9 [72] Coxsackievirus A9 [73] Foot-and-mouth disease virus [74] Japanese encephalitis virus [75] Kaposi's sarcoma-associated herpesvirus [76] Cytomegalovirus [58] Andes virus [77] Adenovirus [78] Rotavirus [79,80] Sin Nombre virus [81]
$\alpha V\beta 5$	Kaposi's sarcoma-associated herpesvirus [82] Adenovirus [78] Epstein-Barr virus [83]
$\alpha V\beta 6$	Coxsackievirus A9 [73] Foot-and-mouth disease virus [84,85] Epstein-Barr virus [83] Herpes simplex virus [86]
$\alpha V\beta 8$	Epstein-Barr virus [83] Herpes simplex virus [86]
$\alpha X\beta 2$	Rotavirus [60]
$\alpha IIb\beta 3$	Sin Nombre virus [81]




Figure 3. Viruses hijack integrins for adhesion and infectivity. Virus families use specific integrins in order to adhere to target cells for the purposes of internalization and infectivity. Members of the family *Adenoviridae* are non-enveloped viruses with icosahedral capsids that have penton base structures which facilitate RGD-dependent docking with $\alpha V\beta 1$, $\alpha V\beta 3$, $\alpha V\beta 5$, and $\alpha 5\beta 1$ integrins as well as the RGD-independent engagement of $\alpha 3\beta 1$. Adenoviruses also target $\alpha M\beta 2$ integrin through an undetermined mechanism. *Birnaviridae* contains members who employ a fibronectin-mimicking IDA peptide to bind $\alpha 4\beta 1$ integrin. Members of the *Flaviviridae* family have an RGD-containing E-protein which binds $\alpha V\beta 3$ integrin. Viruses in the family *Hantaviridae* target the plexin-semaphorin-integrin (PSI) domain of $\alpha V\beta 3$ and $\alpha IIb\beta 3$ integrins. *Herpesviridae* has members that employ a few different mechanisms of integrin engagement for the purposes of viral entry. The envelope protein BMRF-2 contains an RGD sequence that docks $\alpha 5\beta 1$ integrin. The envelope proteins gH and gL dock with $\alpha V\beta 5$, $\alpha V\beta 6$, and $\alpha V\beta 8$. Another envelope protein, known as gB, contains both an RGD motif and disintegrin-like domain, which affords viral targeting of $\alpha V\beta 3$, $\alpha V\beta 5$, $\alpha 2\beta 1$, $\alpha 3\beta 1$, $\alpha 6\beta 1$, and $\alpha 9\beta 1$ integrins. Members of the *Picornaviridae* family use capsid proteins to target integrins. The targeting of $\alpha 2\beta 1$ integrin proceeds in an RGD-independent manner, while $\alpha V\beta 1$, $\alpha V\beta 3$, $\alpha V\beta 6$, and $\alpha 5\beta 1$ integrins are bound in an RGD-dependent fashion. *Reoviridae* contains members which employ a DGE sequence within a VP4 capsid protein to engage $\alpha 2\beta 1$. Additionally, the reovirus VP7 capsid protein has a GPR tripeptide which recognizes $\alpha X\beta 2$, an LDV tripeptide that ligates $\alpha 4\beta 1$, and a novel NEWLCNPDM amino acid sequence that targets $\alpha V\beta 3$. *Togaviridae* has members which have a collagen-mimicking spike protein that docks $\alpha 1\beta 1$ integrin.

3.1. Non-ECM Integrin Ligands of Picornaviridae

Viruses of the *Picornaviridae* family cause a variety of human diseases including aseptic (viral) meningitis, paralysis, hepatitis, and poliomyelitis [87], and there are currently no approved treatments to minimize picornavirus infection. Picornaviruses are non-enveloped viruses with icosahedral capsids, with each face of the 20-sided capsid consisting of three capsid proteins (VP1-3) to form a protomer with 60 subunits. The VP4 protein is contained within the capsid and is thought to help package the single-stranded RNA genome (reviewed in [88]). Several picornaviruses have been shown to exploit integrins as cell surface receptors to facilitate cell invasion. In most cases, the non-ECM ligands that enable picornavirus binding to integrins are located on the VP1-3 capsid proteins.

Members of *Picornaviridae* include the enteric cytopathic human orphan (echo) viruses. Echovirus 1 (EV1) utilizes the $\alpha 2I$ functional domain of $\alpha 2\beta 1$ integrin as a docking receptor on the surface of a target cell [56,57]. Although the precise peptide sequence of EV1 that binds to $\alpha 2\beta 1$ integrin has not been discovered, it is known that EV1 binds to the $\alpha 2I$ domain of $\alpha 2\beta 1$ integrin

10 times more tightly than collagen [56,89,90]. The structure of the EV1 capsid provides a pentameric arrangement of binding sites for $\alpha 2\beta 1$, which induces the clustering of $\alpha 2\beta 1$ integrins, and is thought to promote the entry of the virus [56]. During infection, EV1 along with $\alpha 2\beta 1$ integrin are taken into the host cell via caveolar endocytosis and moved to a caveosome, where it is thought that the virus ejects its genome into the cytosol [91–94]. While EV1 utilizes a non-RGD signal to bind its integrin receptor, echovirus 9 (EV9) docks to integrin $\alpha V\beta 3$ via an RGD domain located on the EV9 VP1 capsid protein [72]. RGD motifs are also thought to be critical in host cell attachment for echovirus 22 (EV22) to $\alpha V\beta 1$ integrins [69,70]. Another member of the *Picornaviridae* family, coxsackievirus A9, utilizes the coxsackievirus and adenovirus receptor (CAR) together with an RGD motif situated in the C-terminal of its VP1 to bind $\alpha V\beta 3$ and $\alpha V\beta 6$ integrins and gain cellular entry [73,95]. Yet another member of the *Picornaviridae* family, foot-and-mouth disease virus (FMDV), is a major scourge of animal husbandry. The VP1 protein of FMDV has an exposed flexible loop, termed the GH loop, which contains an RGD motif and mediates binding to host $\alpha 5\beta 1$, $\alpha V\beta 3$, and $\alpha V\beta 6$ integrins [64,74,84,85].

3.2. Non-ECM Integrin Ligands of Flaviviridae

Flaviviridae is a family of single-stranded, positive sense RNA viruses that are commonly transmitted to human hosts from arthropods such as ticks and mosquitos [96]. Japanese encephalitis virus (JEV), a mosquito-borne member of the genus *Flavivirus*, is a leading cause of viral encephalitis in humans and animals [97,98]. JEV has an envelope protein, called E protein, which contains an RGD motif [99]. Data suggest that JEV utilizes this RGD motif to bind $\alpha V\beta 3$ integrin to aid in cellular infection. Specifically, JEV infectivity is reduced by shRNA knockdown of integrin αV and $\beta 3$ subunits, pretreatment of cells with soluble RGD peptides, or $\alpha V/\beta 3$ blocking antibodies. Conversely, the expression of $\beta 3$ integrin promotes infectivity in otherwise resistant cell lines [75]. Finally, the utilization of integrin receptors appears to be a common infection strategy for the *Flaviviridae* family, since other members such as West Nile virus [100–102], Murray Valley encephalitis virus [103], dengue virus [104], and yellow fever virus [105] have all been connected with integrin-mediated infection or have at least been demonstrated to possess RGD-containing E proteins.

3.3. Non-ECM Integrin Ligands of Herpesviridae

Members of the *Herpesviridae* family of viruses also use integrins for cellular attachment and entry. Epstein-Barr virus (EBV) utilizes $\alpha 5\beta 1$ integrin for infectivity in tongue and nasopharyngeal epithelium by binding host cell integrins with its RGD-containing envelope glycoprotein, BMRF-2 [65]. In addition, the engagement of EBV envelope glycoproteins gH and gL with $\alpha V\beta 5$, $\alpha V\beta 6$, and $\alpha V\beta 8$ integrins induces a conformation in these glycoproteins which facilitates fusion with the target cell membrane [83]. More mechanistic insight is provided by herpes simplex virus (HSV), which also uses gH and gL envelope glycoproteins to dock $\alpha V\beta 6$ and $\alpha V\beta 8$ integrins, and this engagement routes HSV to acidic endosomes, thus promoting viral entry [86]. Another herpes virus, Kaposi's sarcoma-associated herpesvirus (KSHV), uses $\alpha V\beta 3$ [76], $\alpha V\beta 5$ [82], and $\alpha 3\beta 1$ [61] integrins as entry receptors. The expression of the envelope protein, known as glycoprotein B (gB), which is highly conserved across *Herpesviridae* and contains an RGD sequence near its N-terminus, affords KSHV its integrin-binding capacity. However, RGD-mediated binding is not the only mechanism of KSHV-integrin interaction. KSHV glycoprotein B also contains a disintegrin-like domain (DLD) which is capable of binding integrin $\beta 1$ in an RGD-independent fashion [58]. Walker et al. discovered that $\alpha 9\beta 1$ is the integrin target of the glycoprotein B DLD and plays a critical role in KSHV infection [67]. This mechanism is not unusual among *Herpesviridae* family members, as human cytomegalovirus (HCMV) also uses gB to bind $\alpha V\beta 3$, $\alpha 2\beta 1$, and $\alpha 6\beta 1$ through its disintegrin-like domain [58,106].

3.4. Non-ECM Integrin Ligands of Togaviridae

Ross River fever is a mosquito-borne disease caused by the Ross River virus (RRV), a member of the *Togaviridae* family. This disease induces arthritis by the viral infection of macrophages within synovial

joints [107]. It is believed that the RRV spike protein, known as E2, contains two conserved domains which fold in a manner that mimics collagen IV [55]. This allows for the infection of mammalian cells by docking the collagen receptor, $\alpha 1\beta 1$ integrin, in matrix-binding adherent cell types [55].

3.5. Non-ECM Integrin Ligands of Adenoviridae

Human adenoviruses, known for causing respiratory, gastrointestinal, and ocular infections, are non-enveloped viruses with icosahedral capsids. At each capsid vertex, a penton base supports a fiber protein [108]. Many adenoviruses require two receptors for efficient infection of cells. The coxsackievirus and adenovirus receptor (CAR) is required for the initial adhesion of adenoviral particles to target cells, while subsequent integrin engagement is required for the internalization of the viral particle [109]. It is the penton base structure that affords adenoviruses a diverse array of integrin targets. RGD peptide sequences are located atop each monomer of the penton base, forming an RGD ring around the fiber protein [78]. The RGD peptides mediate docking to $\alpha V\beta 1$, $\alpha V\beta 3$, $\alpha V\beta 5$, and $\alpha 5\beta 1$ integrins for the purpose of internalization [66,71,110–112]. Mechanistically, it is thought that the pentameric structure of the base stimulates integrin clustering and downstream integrin signaling, which further facilitates viral internalization [113–115]. Adenoviruses also interact with the laminin binding integrin, $\alpha 3\beta 1$, via its penton base, but in a manner that is RGD-independent [62]. Additionally, $\alpha M\beta 2$ integrin on myeloid cells can be targeted by adenoviruses, but this interaction is dictated through an as yet undetermined sequence within the penton base [68].

3.6. Non-ECM Integrin Ligands of Hantaviridae

As a member of the *Hantaviridae* family, the rodent-targeting Andes virus can spread to humans through the inhalation of aerosolized excreted virus, targeting human endothelial cells and resulting in several fatal diseases such as hantavirus hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome [116]. The infection of $\alpha V\beta 3$ integrin-expressing endothelial cells occurs through the viral targeting of the PSI domain within the $\beta 3$ subunit [77]. Interestingly, a human polymorphism that has a leucine to proline substitution at position 33 of the integrin $\beta 3$ PSI domain was experimentally shown to abolish Andes virus infectivity [77]. Sin Nombre virus also utilizes $\beta 3$ -containing integrins, such as $\alpha IIb\beta 3$ and $\alpha V\beta 3$, for viral attachment [81]. Using atomic force microscopy (AFM) to study membrane dynamics upon Sin Nombre virus interaction, more mechanistic insight was provided for integrin-dependent hantavirus infectivity. Bondu et al. used AFM data to propose a model in which viral docking to the $\beta 3$ PSI domain of $\alpha IIb\beta 3$, when the integrin is in a low affinity state, enhances integrin *cis* interaction with an RGD-containing G-protein coupled receptor known as P2Y₂R [117]. This *cis* interaction is thought to induce a switchblade-like conformational change within the integrin that ultimately leads to the endocytosis of the viral bound integrin [117]. Other pathogenic hantaviruses also bind and cause the dysregulation of $\beta 3$ integrins, resulting in the blockade of endothelial cell migration [118], and the enhancement of vascular endothelial growth factor (VEGF)-mediated vascular permeability [119].

3.7. Non-ECM Integrin Ligands of Birnaviridae

Infectious bursal disease virus (IBDV) is an immunosuppressive avian pathogen in the *Birnaviridae* family that attacks the bursa of Fabricius (the site of hematopoiesis in birds) of young chickens, having a major negative impact on the poultry industry. The IBDV capsid is built by 260 trimers of the VP2 polypeptide arranged in an icosahedral lattice [120]. VP2 is the only component of the virus capsid, and contains a conserved, fibronectin-mimicking IDA peptide sequence that binds to $\alpha 4\beta 1$ integrins present on target cell membranes [63]. IBDV binding to $\alpha 4\beta 1$ integrin triggers c-Src tyrosine phosphorylation and actin rearrangement, which creates membrane protrusions that internalize the virus [121].

3.8. Non-ECM Integrin Ligands of Reoviridae

The family *Reoviridae* includes the gastrointestinal pathogens, known as the rotaviruses, which are the leading etiological factor of diarrheal disease in young children worldwide [122]. The outer layer

of the rotavirus capsid consists of 60 VP4 spike proteins protruding from a VP7 protein shell [123]. It is these outermost structures which mediate host cell binding and infectivity. The VP4 spike protein subunit, VP5, contains a DGE tripeptide sequence that serves to recognize $\alpha 2\beta 1$ integrin on target cells [59,60]. Rotavirus VP7 contains an $\alpha X\beta 2$ -recognizing GPR tripeptide, as well as an $\alpha 4\beta 1$ ligating LDV motif, embedded in a disintegrin-like domain of the protein [60]. Additionally, rotaviruses can target $\alpha V\beta 3$ integrin for the purpose of cellular entry; however, this binding does not occur within the RGD pocket [80]. Rather, it is a novel $\alpha V\beta 3$ -targeting NEWLCNPDM amino acid sequence within the VP7 protein that is thought to mediate rotavirus- $\alpha V\beta 3$ interaction [79]. It has been proposed that reoviruses employ a sequential binding mechanism to multiple receptors for the purpose of internalization. Initial binding to the counterreceptor JAM-A is thought to position the virus for subsequent binding to $\beta 1$ containing integrins that facilitate internalization [124].

4. Non-ECM Integrin Ligands in Venoms

Selectively blocking integrins is a major therapeutic goal when combatting a number of pathologies, and a wide variety of approaches have been initiated. One rich source for anti-integrin compounds are venoms from various snake species [125,126], and the study of venom-derived integrin antagonists remains an active area of research. A venom is defined as a secreted toxin, produced by various types of animals, which is injected into another animal for the purpose of defense or predation. The Viperidae family of snakes (collectively known as the vipers) produce a venom which causes local necrosis and blood coagulation within their prey. The discovery of small integrin-targeting peptides found in the venom of these snakes initiated the study of disintegrins. These small molecular weight (40–100 amino acids in length), non-enzymatic proteins were originally characterized by their platelet-disrupting properties through antagonistic targeting of $\alpha IIb\beta 3$ integrin [127]. Since the identification of the first disintegrins, the field has grown with the discovery of many more examples. As discussed below, major families of venom-derived disintegrins include the RGD, MLD, PIII, and KTS/RTS disintegrins. On the other hand, C-type lectin-like proteins are an example of non-disintegrin toxins, which also disrupt integrin activity. Integrin-targeting venomous compounds are summarized in Table 3.

Table 3. Integrin binding by small molecules, hormones, growth factors, and venoms.

Integrin	Non-ECM Ligand	Function [Key Refs]
$\alpha 1\beta 1$	KTS/RTS disintegrins	Block cell adhesion [128,129]
$\alpha 2\beta 1$	EMS16 CLP	Block adhesion to collagen [130,131]
$\alpha 3\beta 1$	VEGF	Cell adhesion [132]
$\alpha 4\beta 1$	Disintegrin Lebein 1/2	Block cell adhesion [133]
$\alpha 4\beta 7$	MLD disintegrins	Block cell adhesion [128]
$\alpha 5\beta 1$	MLD disintegrins	Block cell adhesion [128]
$\alpha 6\beta 1$	ANGPTL2	Cancer cell migration/proliferation [134]
$\alpha 7\beta 1$	Disintegrin Lebein 1/2	Macrophage pro-inflammatory response [135]
$\alpha 9\beta 1$	Disintegrin Lebein 1/2	Block cell adhesion [133]
$\alpha V\beta 3$	VEGF-A, -C, -D	Block cell adhesion [128]
	MLD disintegrins	Endothelial adhesion & lymphangiogenesis [136]
	Resveratrol	Block cell adhesion [128]
	Thyroid hormones (T3/T4)	Anti-angiogenesis [137–139]
	DHT	Cell proliferation/angiogenesis [140–142]
	ANGPTL3	Cancer cell proliferation [143,144]
	ANGPTL4	Podocyte motility [145]
	VEGF	Enhanced endothelial junctions [146]
$\alpha V\beta 5$	ANGPTL4	Endothelial cell adhesion [132]
$\alpha V\beta 6$	Pro-TGF β	Reduce proteinuria [147]
		TGF β activation [148,149]

Abbreviations: lysine-threonine-serine (KTS), arginine-threonine-serine (RTS), C-type lectin-like protein (CLP), vascular endothelial growth factor (VEGF), methionine-leucine-aspartic acid (MLD), angiopoietin-like protein (ANGPTL), dihydrotestosterone (DHT), transforming growth factor β (TGF β)

The RGD family of disintegrins is the largest family, although RGD amino acid sequences are not strictly required to be members in this family. Instead, disintegrins containing RGD or similar amino acid motifs, such as KGD, MGD, VGD, and WGD, are all capable of targeting RGD-binding integrins, serving to disrupt their physiological functions. Moreover, not all RGD disintegrins target RGD-binding integrins exclusively. For example, lebein1 and lebein2 are two RGD-containing disintegrins found in the venom of *Macrovipera lebetina*, which have the unusual property of targeting the laminin-binding integrins $\alpha 3\beta 1$, $\alpha 6\beta 1$, and $\alpha 7\beta 1$ in an RGD-independent fashion [133]. They are thought to mimic the integrin-binding motif of laminin, thus allowing these molecules to disrupt cellular attachment to the laminin-rich basement membrane [133].

Other disintegrin families include the MLD-, PIII-, and KTS/RTS-containing disintegrins. Whereas the RGD family of disintegrins possesses an RGD tripeptide (or similar motif) within the integrin-binding loop of the protein, the MLD motif is found at this same position in MLD-containing disintegrins [128]. These MLD disintegrins appear in heterodimeric complexes and are highly dependent on adjacent sequences to target the $\alpha 4\beta 1$, $\alpha 4\beta 7$, and $\alpha 9\beta 1$ leukocyte specific receptor family of integrins [128]. PIII class disintegrins are large multi-domain toxins (60–100 kDa) which use an ECD integrin-targeting tripeptide and contain a metalloprotease domain which is a close homolog to the ADAM (a disintegrin and metalloprotease) family of metalloproteases [150]. The disintegrin known as alternagin uses an ECD tripeptide motif to target $\alpha 2\beta 1$ integrin and disrupt matrix binding [151]. Once bound, alternagin uses its protease domain to cleave $\beta 1$, causing integrin shedding and further disruption of collagen-induced platelet aggregation [152]. Finally, the KTS/RTS group of disintegrins, found in Viperidae venom, are monomeric proteins which bind the collagen receptor $\alpha 1\beta 1$ integrin [129]. This high level of specificity is not matched by RGD and MLD disintegrins, as KTS/RTS disintegrins only target $\alpha 1\beta 1$ integrin [128].

Another class of toxin found in Viperidae venom is the C-type lectin-like proteins (CLPs). These proteins do not exhibit the sugar-binding capabilities of C-lectin proteins, but instead target collagen-binding integrins [153]. The viper species *Echis carinatus multisquamatus* produces EMS16, a potent and selective inhibitor of $\alpha 2\beta 1$ integrin [130]. X-ray crystallography reveals that EMS16 spatially blocks collagen-integrin ligation through docking with the $\alpha 2I$ domain of $\alpha 2\beta 1$ integrin and stabilizing a low matrix affinity integrin conformation [131]. Several studies have shown that many viper-derived CLPs target endothelium and block angiogenesis [130,154,155], while applying CLPs to cancer cells can inhibit cell-collagen binding [153] and metastasis [156]. Integrins that interact with CLPs are summarized in Table 3.

5. Bacterial Use of Non-ECM Integrin Ligands

For many bacterial cells, successful adhesion to host cell surfaces is a prerequisite for successful colonization and/or infection. Many bacteria take advantage of the binding capabilities of integrins on cell membranes for infectious purposes. Some bacteria utilize specific integrin dimers for cellular binding, while others exploit extracellular fibrous proteins that naturally bind to integrins for the purpose of translocating virulence factors. For this review, we will highlight three of the most commonly studied interactions between bacteria and integrins. There are other notable examples of bacterial cells using integrins as host cell receptors that we will not discuss: the intimin protein of *Escherichia coli* that binds to $\alpha 4\beta 1$ and $\alpha 5\beta 1$ integrins [157], the IpaB, C, and D proteins of *Shigella flexneri* that bind to $\alpha 5\beta 1$ integrin [158], and the filamentous hemagglutinin protein of *Bordetella pertussis* that binds to $\alpha M\beta 2$ integrin [159]. Integrins that participate in bacterial interactions are listed in Table 4.

5.1. Non-ECM Integrin Ligands of *Borrelia burgdorferi*

The spirochete *Borrelia burgdorferi* is the causative agent of Lyme disease, a devastating disease of the nervous system. The natural reservoir for *B. burgdorferi* includes mice, birds, and lizards [160]. These spirochetes are transmitted to humans via tick vectors of the *Ixodes* genus [160]. Once injected

into the blood stream, *B. burgdorferi* spirochetes adhere to the microvasculature, transmigrate through the endothelium, and disseminate into various tissues [161]. Characterizing the proteins that enable this pathological mechanism illustrates several interesting examples of how microbes take advantage of host integrins.

A variety of screening techniques have identified at least 19 *B. burgdorferi* proteins that mediate or enhance adhesion to target cells [162]. The majority of these proteins mediate indirect adhesion to mammalian cells via interactions with various ECM molecules. Three proteins however, P66, BBB07, and BB0172, have been shown to interact with integrins on platelets and a variety of cells such as endothelial cells. Prior to the discovery of the P66 protein, it had been known for some time that *B. burgdorferi* cells could adhere to $\beta 3$ chain-containing integrins [163,164]. The P66 protein was later identified by phage display and shown to bind $\alpha V\beta 3$ and $\alpha IIb\beta 3$ integrins [165]. P66 displays no typical integrin-binding sites [165], although the adhesion of P66 to integrins can be blocked by soluble RGD peptides, suggesting that P66 may bind into the RGD pocket of $\beta 3$ integrins [166]. Moreover, a minimal seven-amino acid sequence (QENDKDT) from P66 was found to bind integrins, and the deletion of the aspartic acid residues from this peptide eliminated P66 integrin binding [167]. Despite the integrin-binding activity of P66, the deletion of P66 does not appear to affect *B. burgdorferi* adhesion to microvasculature, a key step preceding tissue invasion [168]. Instead, the P66 protein (presumably via its integrin-binding activity) appears to be essential for the endothelial transmigration and dissemination of *B. burgdorferi* spirochetes into host tissues [167,168]. Although P66 deletion did not affect microvascular adhesion, *B. burgdorferi* binding to various cells can be blocked by soluble RGD peptides [163], suggesting the presence of other integrin-binding proteins. In support of this, two additional integrin-binding outer membrane surface proteins, BBB07 and BB0172, have been detected on *B. burgdorferi* [169,170]. Although both BBB07 and BB0172 have been shown to interact with $\alpha 3\beta 1$ integrins, only BBB07 contains an RGD motif [170]. Currently, there is little known about the function of $\alpha 3\beta 1$ integrins in endothelial biology, although it has been proposed that $\alpha 3\beta 1$ binding to Laminin 511 in the basal lamina may be linked to endothelial barrier function [171], which could provide a link to the transendothelial migration of *B. burgdorferi* during infection.

5.2. Non-ECM Integrin Ligands of *Helicobacter pylori*

Helicobacter pylori infects roughly half of the world's human population and shares responsibility for gastric complications including stomach ulcers and gastric adenocarcinoma through its infection of gastric epithelial cells [172–174]. *H. pylori* utilizes a type IV protein secretion system (T4SS) involving the cytotoxin-associated gene L (CagL) adhesion tip protein to infect target cells with the virulence factor, cytotoxin-associated gene A (CagA) [175,176]. The efficiency of CagA injection is enhanced by an RGD domain present on the CagL protein [177]. CagL interacts primarily with $\alpha 5\beta 1$ integrin; however, $\alpha V\beta 3$, $\alpha V\beta 5$, and $\alpha V\beta 6$ have also been implicated [178–181]. Interestingly, while the CagL RGD domain is necessary for CagA injection, additional CagL sequences have been identified that enhance integrin binding. For example, an RGD helper sequence, FEANE, is located in close proximity to the RGD domain of CagL and reinforces integrin engagement [177]. Additional domains on CagL that enhance RGD binding include a TSPSA sequence [182], an LXXL sequence that is directly adjacent to the RGD domain [181], and a TASLI sequence located opposite the RGD domain in the CagL integrin-binding domain [182]. CagL- $\alpha 5\beta 1$ interaction leads to the activation of the kinases Src and FAK [179], followed by subsequent tyrosine phosphorylation of the CagA EPIYA amino acid motifs by Src and ABL kinases [183]. These phosphorylation events potentiate CagA pathogenicity (reviewed in [184]). Phospho-CagA interacts with Shp-2 while initiating mitogen-activated protein kinase (MAPK) signaling, and inducing cytoskeletal rearrangements which serve to cause an elongation of epithelial cells and enhance their mobility. CagA also disrupts cell-cell junctions while triggering an inflammatory response, including nuclear factor- κB (NF- κB) activation and chemokine production. Additionally, in a negative feedback loop phospho-CagA downregulates Src activity, ensuring that a reservoir of nonphospho-CagA remain in the cell, which is necessary for a prolonged infection. As mentioned previously, CagL is capable of interacting

with other integrins. Interestingly, a novel mechanism of CagL- α V β 5-induced production of gastrin has been uncovered. It was found that CagL ligation to α V β 5 on gastric epithelial cells activates ILK, which in turn activates the epidermal growth factor receptor (EGFR) and subsequently MAPK pathways, serving to induce gastrin expression [178]. This mechanism may explain *H. pylori* induced hypergastrinemia, which is a major risk factor for gastric adenocarcinoma. The integrin-dependent mechanisms of *H. pylori* infection discussed here are depicted in Figure 2.

5.3. Non-ECM Integrin Ligands of *Yersinia*

The Gram-negative bacteria *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* commonly cause foodborne illnesses. These *Yersinia* species express two adhesion proteins that facilitate cellular attachment and invasion of target cells in the small intestine. The *Yersinia* adhesion A (YadA) protein indirectly binds to integrins via interaction with various molecules of the ECM, but is dispensable for cellular invasion [185,186]. However, the *Yersinia* invasin protein directly binds to a variety of β 1 subunit-containing integrins (α 3, α 4, α 5, α 6, α V) and is crucial for cellular adhesion and invasion [187,188]. *Yersinia* species invading through the small intestine target the apical membrane of Peyer's patch M-cells, which express integrin β 1 [189,190]. Invasins lack the typical RGD domain used to bind integrins, although RGD peptides prevent invasin binding to β 1 integrins [191]. This suggests that invasin proteins interact with the RGD binding domain of β 1-containing integrin heterodimers. In support of this, the structural analysis of the invasin protein, and comparison to fibronectin, reveals similar structures with key conserved integrin-binding residues, suggesting the convergent evolution of invasins to match fibronectin [192].

Table 4. Integrin binding by bacteria and parasitic organisms.

Integrin	Species	Binding Protein [Key Refs]
α 2 β 1	<i>Ancylostoma caninum</i>	Hookworm platelet inhibitor (HPI) [193,194]
α IIb β 3	<i>Ancylostoma caninum</i>	Hookworm platelet inhibitor (HPI) [193,194]
	<i>Macrobdeella decora</i>	Decorsin [195]
	<i>Tabanus yao</i>	Vasotab TY [196]
	<i>Ornithodoros moubata</i>	Tablysin-15 [197]
	<i>Ixodes pacificus</i>	Disagregin [198]
	<i>Dermacentor variabilis</i>	YY-39 [199]
		Variabilin [200]
α 3 β 1	<i>Borrelia burgdorferi</i>	BBB07, BB0172 [170]
	<i>Yersinia</i>	Invasin [187,188]
α 4 β 1	<i>Escherichia coli</i>	Intimin [157]
	<i>Yersinia</i>	Invasin [187,188]
α 5 β 1	<i>Helicobacter pylori</i>	CagL [177,179]
	<i>Escherichia coli</i>	Intimin [157]
	<i>Shigella flexneri</i>	Ipa B, C, D [158]
	<i>Entamoeba histolytica</i>	EhCP5 [201]
	<i>Yersinia</i>	Invasin [187]
α 6 β 1	<i>Yersinia</i>	Invasin [187,188]
α M β 2	<i>Bordetella pertussis</i>	Filamentous hemagglutinin protein [159]
	<i>Ancylostoma caninum</i>	Neutrophil inhibitor factor (NIF) [202]
α V β 1	<i>Yersinia</i>	Invasin [187]
α V β 3	<i>Borrelia burgdorferi</i>	P66 [165]
	<i>Helicobacter pylori</i>	CagL [177]
	<i>Entamoeba histolytica</i>	EhCP5 [203,204]
α V β 5	<i>Helicobacter pylori</i>	CagL [178,180]
α V β 6	<i>Helicobacter pylori</i>	CagL [181]

6. Protists and Multicellular Parasites That Use Non-ECM Integrin Ligands

A broad array of examples of non-ECM ligands for integrins are employed by many parasitic organisms. Here we discuss just a few examples, including non-ECM ligands produced by the amoebozoan *Entamoeba histolytica* and a range of hematophagic (blood-sucking) organisms. These examples illustrate the importance of non-ECM ligands to parasitic infections. Although compared to bacteria and viruses, there is far less literature on the subject of non-ECM ligands as components of pathogenicity in protozoan and multicellular parasites. Non-ECM integrin ligands derived from parasitic organisms are summarized in Table 4.

6.1. Non-ECM Integrin Ligands of *Entamoeba histolytica*

Entamoeba histolytica (Eh) causes amoebic dysentery and liver abscess [205] and is responsible for ~100,000 deaths/year [206]. Eh invasion into host tissues involves multiple integrin-mediated steps. The best-characterized of these integrin-mediated steps involves the Eh cysteine protease 5 (EhCP5) binding to $\alpha V\beta 3$ integrins [203,204]. The binding of EhCP5 to $\alpha V\beta 3$ integrins on colonic epithelial cells via an RGD domain triggers NF- κ B-mediated inflammation [203] and mucin exocytosis [204]. The EhCP5 protein has also been shown to interact with $\alpha 5\beta 1$ integrins to mediate local inflammation, which is crucial to Eh invasion into host tissues [201]. Additional involvement of integrins in Eh invasion has been linked to $\beta 2$ integrin activation and release of reactive oxygen species [207,208] as well as an integrin $\beta 1$ -like receptor present on Eh trophocytes that mediates adhesion to host fibronectin [209].

6.2. Non-ECM Integrin Ligands of Hookworms

The hookworm platelet inhibitor (HPI) protein illustrates another fascinating example of non-ECM integrin ligands. Hookworms are blood-feeding intestinal parasites and a leading cause of iron deficiency in humans. HPI was isolated from the hookworm *Ancylostoma caninum* based on its ability to inhibit the function of integrins $\alpha IIb\beta 3$ and $\alpha 2\beta 1$ [193,194]. HPI appears to block platelet aggregation and blood clotting, thus enabling continued feeding. Interestingly, sequence and structural analysis has failed to identify any integrin-binding domains in the HPI protein [210]. In addition to the HPI protein, *Ancylostoma caninum* also expresses the neutrophil inhibitor factor (NIF) that interacts with $\alpha M\beta 2$ integrins present on neutrophils [202,211]. NIF disrupts $\alpha M\beta 2$ interaction with ICAM1 [202], which is necessary for stable neutrophil adhesion to the endothelium and transendothelial migration, thus suppressing local inflammation. Collectively, the combined actions of HPI and NIF help ensure that hookworms are able to feed from their host for a prolonged period of time.

6.3. Non-ECM Integrin Ligands of Blood-Sucking Parasites

In addition to *Entamoeba histolytica* and *Ancylostoma caninum*, several other examples of integrin inhibition by hematophagic (blood-sucking) animals have been described in the literature (reviewed in [212]). Many of these strategies involve non-ECM integrin ligands that interfere with various integrin-mediated steps that are essential for blood coagulation. The majority of these non-matrix ligands block platelet $\alpha IIb\beta 3$ integrin interactions with fibrin, von Willebrand factor, and vitronectin, which are collectively essential for blood coagulation. Many of these integrin disrupting molecules are found in the saliva of hematophagic organisms and not only inhibit platelet aggregation, but also disrupt neutrophil function and angiogenesis [212]. Examples of these integrin disrupting proteins include the decorsin protein from the leech *Macrobdella decora* [195], the vasotab TY and tablysin-15 proteins from the horsefly *Tabanus yao* [196,197], and the disagregin (*Ornithodoros moubata*), YY-39 (*Ixodes pacificus* and *Ixodes scapularis*), and variabilin (*Dermacentor variabilis*) proteins from ticks [198–200]. Many of these proteins contain RGD or similar integrin-binding amino acid motifs (KGD, VGD, MLD, KTS, RTS, WGD, or RED) which bind to and interfere with $\alpha IIb\beta 3$ integrin function on platelets. Additional RGD or RGD-like integrin antagonists

have been identified *in silico* from other blood-sucking arthropods such as mosquitos and sand flies [212], but have yet to be explored.

7. Hormones, Small Molecules, and Growth Factors That Mimic Integrin Ligands

To this point, we have focused on the non-ECM integrin ligands utilized by various organisms to mediate adhesion to target cell membranes. However, as it turns out, a wide variety of small molecules (including hormones and growth factors) can also interact with integrins, thus broadening the role for integrins in non-ECM interactions. As described in the examples below, integrins binding to small molecules serve a number of cellular functions ranging from cell surface receptor-signaling roles, as in the case of thyroid hormone, dihydrotestosterone, angiopoietin-like proteins (ANGPTLs), and VEGF, to the activation of growth factors, as in the case of TGF β . Integrins that interact with hormones, small molecules, or growth factors are summarized in Table 3 and depicted in Figure 4.




Figure 4. Integrins serve as cell surface receptors for growth factors, hormones, and small molecules. Various growth factors use integrins as cell surface receptors. Angiopoietin-like proteins (ANGPTLs) bind α 5 β 1 and α V β 3 integrins to facilitate a host of cellular effects. Pro-TGF β is activated by α V β 3, α V β 5, α V β 6, and α V β 8 through the integrin-dependent dissociation of an RGD-containing latency-associated peptide (LAP), thus converting it to its active form. Activated TGF β acts as a master regulator of fibrosis, among other roles. Vascular endothelial growth factor (VEGF) ligates α 3 β 1, α 9 β 1, α V β 3, and other α V-containing integrins, resulting in cellular effects that promote angiogenesis and lymphangiogenesis. The polyphenol trans-resveratrol, which is derived from grapevines, binds the β 3 subunit of α V β 3 integrin near the RGD recognition pocket. This binding event induces extracellular signal-regulated kinase (ERK) activation and p53-dependent apoptosis, while promoting angiostasis. Like trans-resveratrol, the active form of testosterone (DHT) also binds the β 3 subunit of α V β 3 integrin near the RGD pocket. DHT- α V β 3 interaction inhibits trans-resveratrol-induced effects and stimulates cellular proliferation. The thyroid hormones, T3 and T4, utilize α V β 3 integrin as a cell surface receptor to activate a range of signaling molecules which induce angiogenesis. When binding to α V β 3 integrin, the thyroid hormone analog tetrac blocks T3/T4 integrin-induced effects.

7.1. Small Molecules and Hormones That Bind Integrins (Resveratrol, Thyroid Hormone, DHT)

Trans-resveratrol is a stilbenoid produced in plants such as grapevines that is well-known for its anti-inflammatory activity [213], anti-angiogenic function [214], and anticancer properties [215–217].

Resveratrol binds the extracellular portion of the $\beta 3$ monomer of $\alpha V\beta 3$ integrin near the RGD pocket [137]. This binding inhibits $\alpha V\beta 3$ integrin-dependent endothelial cell adhesion to vitronectin-coated plates, while also exhibiting angiostatic function and inhibiting tumor growth [139]. Resveratrol binding to $\alpha V\beta 3$ integrin induces extracellular signal-regulated kinase (ERK1/2) activation, which leads to p53-induced apoptosis in various cancer cell lines [137,138]. This evidence implicates resveratrol binding $\alpha V\beta 3$ integrin as being at least in part responsible for resveratrol's ability to mitigate angiogenesis and tumorigenesis.

Integrin $\alpha V\beta 3$ bears a receptor site for the thyroid hormones T3 and T4 as well as thyroid hormone analogs (reviewed in [140]). Perhaps the first evidence of this interaction was uncovered when Hoffman et al. [218] used an $\alpha V\beta 3$ inhibitor (SB-273005) to block T4-induced bone resorption in rats. The binding of T3 and T4 to $\alpha V\beta 3$ integrin induces cell proliferation and angiogenesis through MAPK activation, and this effect is negated by a T4 derivative tetraiodothyroacetic acid (tetrac), RGD peptide, and $\alpha V\beta 3$ integrin-blocking antibodies, suggesting that the thyroid hormone receptor site is at or near the RGD binding pocket [141–143]. Through radioligand binding experiments, it was shown that purified $\alpha V\beta 3$ integrin binds T4 preferentially over T3, and binds T4 with high affinity, having a dissociation constant (K_d) of 333 pM and an EC_{50} of 371 pM [142]. Lin et al. proposed a model for the thyroid hormone receptor activity of $\alpha V\beta 3$ integrin that describes two distinct thyroid hormone binding sites on $\alpha V\beta 3$ [219]. The site known as “site 1” appears to bind T3 but not T4, while another site called “site 2” binds both T3 and T4 [219]. T3 binding at site 1 leads to Src and phosphatidylinositol 3-kinase (PI3K) activation, which induces nuclear translocation of thyroid hormone receptor (TR) $\alpha 1$, and these effects can be disrupted through the addition of RGD peptide [219]. Meanwhile, T3/T4 binding at site 2 induces ERK activation, which causes nuclear translocation of TR $\beta 1$, and only T4-induced effects at this site are disrupted by RGD peptides [219]. This suggests that $\alpha V\beta 3$ -dependent thyroid hormone signaling acts as a complex, hierarchical system capable of mediating distinct site-specific activities. Since some of these activities are disrupted through RGD binding, and this leads to the possibility that cells embedded in an RGD-rich matrix may respond differentially to thyroid hormone compared to those embedded in an RGD-deficient matrix. Perhaps this is a mechanism by which a ubiquitous receptor, such as $\alpha V\beta 3$, can provide tissue-specific responses to thyroid hormone.

In addition to thyroid hormones, $\alpha V\beta 3$ integrin also interacts with the biologically active form of testosterone, dihydrotestosterone (DHT). Whether or not this interaction is involved in the normal physiological roles of DHT is unknown; however, DHT binding to $\alpha V\beta 3$ has been implicated in cancer cell growth. For example, DHT binding to $\alpha V\beta 3$ stimulates MDA-MB-231 breast cancer cell proliferation [143]. Additionally, DHT binding to $\alpha V\beta 3$ integrin inhibits resveratrol-induced, p53-dependent apoptosis effects in MDA-MB-231 cells [144], thus highlighting the complexity of hormone signaling through $\alpha V\beta 3$ integrin. Through these examples, it is clear that $\alpha V\beta 3$ integrin has diverse receptor activity which affords hormones additional non-canonical signaling capacity.

7.2. Growth Factors That Bind Integrins (ANGPTLs, TGF β , VEGF)

Many growth factors are capable of binding integrins. An interesting example is the angiopoietin-like proteins (ANGPTLs), also known as angiopoietin-related proteins (ARPs), which consist of a family of proteins that display structural similarity to the growth factor angiopoietin, although they do not bind classical angiopoietin receptors [220]. Instead, ANGPTLs have been demonstrated to bind various integrins through a C-terminal fibronectin-like domain containing a conserved RGD sequence [221]. In human prostate cancer (LNCaP) cells, ANGPTL2 binds $\alpha 5\beta 1$ integrin, inducing migration and proliferation, and this effect can be negated by use of integrin-blocking antibodies [134]. Furthermore, ANGPTL2 binding $\alpha 5\beta 1$ integrin on macrophages mediates pro-inflammatory responses in mice, and ANGPTL2 knockout mice have muted immune responses, leaving them more susceptible to infections [135]. In the kidney, glomerular podocyte motility is enhanced through cytoskeletal rearrangement induced by ANGPTL3 binding podocyte $\alpha V\beta 3$ integrin [145]. The deletion of ANGPTL3 can reduce proteinuria in mouse models of

nephropathy, and ANGPTL3 activation of integrin $\beta 3$ has been identified in patients with nephrotic syndrome [222]. The ANGPTL family also affects vascular integrity. In response to decreased albumin levels during peak proteinuria, podocytes and extrarenal tissues secrete ANGPTL4 into the blood, which binds glomerular endothelial $\alpha V\beta 5$ integrin and serves to reduce proteinuria [147]. This effect may be explained by another study where surface plasmon resonance and proximity ligation assays were used to discover that ANGPTL4 also binds another endothelial integrin, $\alpha V\beta 3$, which serves to recruit Src kinase and enhance endothelial junction stability, thereby reducing vascular permeability [146]. Taken collectively, these studies suggest that ANGPTL3 binding podocyte integrins enhances proteinuria, whereas ANGPTL4 binding glomerular endothelial integrins decreases proteinuria. The ANGPTLs are a good example of a protein family that mimics a classical extracellular matrix protein in order to bind integrins and implement their cellular effects.

Integrins also play a critical role in the activation of TGF β (reviewed in [148]). An inactive form of TGF β (pro-TGF β) is secreted from cells with an RGD containing latency-associated peptide (LAP) non-covalently bound to TGF β , which must be removed before TGF β is biologically active. While the RGD binding $\alpha V\beta 6$ integrin plays a key role in separating LAP from TGF β , other αV -containing integrins, including $\alpha V\beta 3$, $\alpha V\beta 5$, and $\alpha V\beta 8$, have been implicated in this process. Mutation of the LAP integrin-binding site in mice yields normal levels of pro-TGF β , but results in a lethal phenotype which appears identical to TGF β deletion [223]. LAP separation is mediated by a tensile force generated by a cell's cytoskeleton that is transmitted via $\alpha V\beta 6$ integrin in order to reshape and activate the pro-TGF β [149]. The dependence of pro-TGF β on $\alpha V\beta 6$ for activation, and the fact that TGF β is a well-known master regulator of fibrosis [224], has led to the suggestion that the inhibition of $\alpha V\beta 6$ integrin binding may represent a clinical strategy to treat diseases characterized by fibrosis, such as scleroderma [225]. This idea is supported by observations showing that $\alpha V\beta 6$ knockout mice [226] or treatment with $\alpha V\beta 6$ blocking antibodies [227,228] substantially decrease fibrosis in mouse models of lung fibrosis.

The vascular endothelial growth factors (VEGFs) comprise a group of cytokines which are important mediators of angiogenesis and lymphangiogenesis. VEGF signaling functions through VEGF binding to a group of receptor tyrosine kinases, known as VEGF receptors (VEGFRs). Since this pathway is an inducer of angiogenesis, it has been the target of many anticancer therapies with the hope of inhibiting tumor vascularization. One therapeutic strategy involves inhibiting VEGF-VEGR binding through the targeting of VEGFRs with monoclonal antibodies [229]. However, this approach has not proven as effective as drug developers and clinicians envisioned [229,230]. One reason for this failure may be that VEGFRs are not the only membrane-bound receptor of VEGFs, as these growth factors are also known to bind integrins. Some VEGF isoforms are integrated into the extracellular matrix, where they bind $\alpha 3\beta 1$, $\alpha V\beta 3$, and other αV integrins to promote endothelial cell adhesion [132]. Interestingly, the solubility of VEGF ligands greatly effects the integrin response. Vlahakis et al. found that when $\alpha 9\beta 1$ integrin binds immobilized VEGF-A, it induces the recruitment of VEGFR2 into macromolecular structures at the cell membrane [136]. This serves to permit endothelial cell adherence and migration on VEGF-A functionalized Petri dishes, and stimulates the phosphorylation of the downstream effectors paxillin and ERK [136]. In contrast, when soluble VEGF binds $\alpha 9\beta 1$ integrin, paxillin is phosphorylated, but neither the phosphorylation of ERK nor the formation of VEGFR2 macromolecular complexes are induced [136]. Moreover, VEGF-A is not the only VEGF member to have these functions. VEGF-C and VEGF-D also bind $\alpha 9\beta 1$ integrin, stimulating the phosphorylation of paxillin and ERK, while contributing to lymphangiogenesis [231]. Taken together, these findings suggest a VEGF-induced synergy between VEGFR and integrins. Therefore, it may be beneficial to co-target integrins when employing an anti-VEGF therapeutic strategy during cancer treatment.

8. Conclusions

Throughout this review, we have sought to venture beyond the matrix and highlight biological examples of integrin ligands that do not fit the classical model of ECM-mediated integrin function.

Given the strong conservation of integrins across much of the biological world, it is no surprise that there exists an extremely diverse array of these non-ECM integrin ligands. Consequently, interactions between integrins and non-ECM ligands are actively being exploited for a number of applications in the biotechnology realm. RGD peptides are being used to target liposomes and small molecules to specific tissues for various purposes, including the improvement of chemotherapeutic delivery to cancer cells [232–234]. Similarly, RGD peptides are also being used to target viral particles to various tissues. For instance, the new field of “chemical virology” seeks to load viral capsids with chemotherapeutics that, in some instances, utilize RGD functionalization to deliver these nanoparticles to specific tissues [235]. In a related example, a plant virus known as the cowpea mosaic virus, which does not normally target mammalian cells, was functionalized with RGD peptides to successfully target cancer cell lines [236]. Demonstrating another example of applied integrin biotechnology, various artificial “extracellular matrices” are now being created and designed with incorporated RGD peptides to enable cell seeding and growth [237]. Two exciting examples include the development of graphene that has been functionalized with RGD peptides, which is being used to detect nitric oxide release from living cells [238], and DNA origami tubes that have been tagged with RGD peptides and shown to bind neural stem cells and promote their differentiation [239]. These instances and many others provide fascinating examples of how the unique binding properties of integrins continue to be uncovered and utilized.

Acknowledgments: This work was supported by funding from the National Institute of General Medical Sciences to Allan R. Albig (2R15GM102852-02) and it was also supported by Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grants #P20GM103408 and P20GM109095.

Author Contributions: Bryce LaFoya, Jordan A. Munroe, Alison Miyamoto, Michael A. Detweiler, Jacob J. Crow, Tana Gazdik, and Allan R. Albig contributed to the literature research of the topic, writing individual sections, and proofreading the final manuscript. Bryce LaFoya designed and constructed all figures. Bryce LaFoya, Jordan A. Munroe, and Allan R. Albig prepared the final manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Humphries, J.D.; Byron, A.; Humphries, M.J. Integrin ligands at a glance. *J. Cell Sci.* **2006**, *119*, 3901–3903. [[CrossRef](#)] [[PubMed](#)]
2. Harburger, D.S.; Calderwood, D.A. Integrin signalling at a glance. *J. Cell Sci.* **2009**, *122*, 159–163. [[CrossRef](#)] [[PubMed](#)]
3. Pancer, Z.; Kruse, M.; Muller, I.; Muller, W.E. On the origin of Metazoan adhesion receptors: Cloning of integrin α subunit from the sponge *Geodia cydonium*. *Mol. Biol. Evol.* **1997**, *14*, 391–398. [[CrossRef](#)] [[PubMed](#)]
4. Brower, D.L.; Brower, S.M.; Hayward, D.C.; Ball, E.E. Molecular evolution of integrins: Genes encoding integrin β subunits from a coral and a sponge. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 9182–9187. [[CrossRef](#)] [[PubMed](#)]
5. Wimmer, W.; Blumbach, B.; Diehl-Seifert, B.; Koziol, C.; Batel, R.; Steffen, R.; Muller, I.M.; Muller, W.E. Increased expression of integrin and receptor tyrosine kinase genes during autograft fusion in the sponge *Geodia cydonium*. *Cell Adhes. Commun.* **1999**, *7*, 111–124. [[CrossRef](#)] [[PubMed](#)]
6. Sebe-Pedros, A.; Roger, A.J.; Lang, F.B.; King, N.; Ruiz-Trillo, I. Ancient origin of the integrin-mediated adhesion and signaling machinery. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 10142–10147. [[CrossRef](#)] [[PubMed](#)]
7. Hynes, R.O. The emergence of integrins: A personal and historical perspective. *Matrix Biol.* **2004**, *23*, 333–340. [[CrossRef](#)] [[PubMed](#)]
8. Hynes, R.O. Integrins: A family of cell surface receptors. *Cell* **1987**, *48*, 549–554. [[CrossRef](#)]
9. Hynes, R.O. Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell* **1992**, *69*, 11–25. [[CrossRef](#)]
10. Sullivan, D.P.; Muller, W.A. Neutrophil and monocyte recruitment by PECAM, CD99, and other molecules via the LBRC. *Semin. Immunopathol.* **2014**, *36*, 193–209. [[CrossRef](#)] [[PubMed](#)]

11. Imhof, B.A.; Aurrand-Lions, M. Adhesion mechanisms regulating the migration of monocytes. *Nat. Rev. Immunol.* **2004**, *4*, 432–444. [[CrossRef](#)] [[PubMed](#)]
12. Zundler, S.; Fischer, A.; Schillinger, D.; Binder, M.T.; Atreya, R.; Rath, T.; Lopez-Posadas, R.; Voskens, C.J.; Watson, A.; Atreya, I.; et al. The $\alpha 4\beta 1$ Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. *Inflamm. Bowel Dis.* **2017**, *23*, 379–391. [[CrossRef](#)] [[PubMed](#)]
13. Rettig, M.P.; Anstas, G.; DiPersio, J.F. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. *Leukemia* **2012**, *26*, 34–53. [[CrossRef](#)] [[PubMed](#)]
14. Ghobadi, A.; Rettig, M.P.; Cooper, M.L.; Holt, M.S.; Ritchey, J.K.; Eissenberg, L.; DiPersio, J.F. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. *Blood* **2014**, *124*, 2752–2754. [[CrossRef](#)] [[PubMed](#)]
15. Bungartz, G.; Stiller, S.; Bauer, M.; Muller, W.; Schippers, A.; Wagner, N.; Fassler, R.; Brakebusch, C. Adult murine hematopoiesis can proceed without $\beta 1$ and $\beta 7$ integrins. *Blood* **2006**, *108*, 1857–1864. [[CrossRef](#)] [[PubMed](#)]
16. Seguin, L.; Desgrosellier, J.S.; Weis, S.M.; Cheresch, D.A. Integrins and cancer: Regulators of cancer stemness, metastasis, and drug resistance. *Trends Cell Biol.* **2015**, *25*, 234–250. [[CrossRef](#)] [[PubMed](#)]
17. Sun, H.; Liu, J.; Zheng, Y.; Pan, Y.; Zhang, K.; Chen, J. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. *Dev. Cell* **2014**, *30*, 61–70. [[CrossRef](#)] [[PubMed](#)]
18. Murakami, J.L.; Xu, B.; Franco, C.B.; Hu, X.; Galli, S.J.; Weissman, I.L.; Chen, C.C. Evidence that $\beta 7$ Integrin Regulates Hematopoietic Stem Cell Homing and Engraftment Through Interaction with MAdCAM-1. *Stem Cells Dev.* **2016**, *25*, 18–26. [[CrossRef](#)] [[PubMed](#)]
19. Maric, G.; Annis, M.G.; Dong, Z.; Rose, A.A.; Ng, S.; Perkins, D.; MacDonald, P.A.; Ouellet, V.; Russo, C.; Siegel, P.M. GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin $\alpha 5\beta 1$ for efficient breast cancer metastasis. *Oncogene* **2015**, *34*, 5494–5504. [[CrossRef](#)] [[PubMed](#)]
20. Le Floch, A.; Jalil, A.; Vergnon, I.; Le Maux Chansac, B.; Lazar, V.; Bismuth, G.; Chouaib, S.; Mami-Chouaib, F. $\alpha E\beta 7$ integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. *J. Exp. Med.* **2007**, *204*, 559–570. [[CrossRef](#)] [[PubMed](#)]
21. O'Brien, X.M.; Reichner, J.S. Neutrophil integrins and matrix ligands and NET release. *Front. Immunol.* **2016**, *7*, 1–7. [[CrossRef](#)] [[PubMed](#)]
22. Doke, M.; Fukamachi, H.; Morisaki, H.; Arimoto, T.; Kataoka, H.; Kuwata, H. Nucleases from *Prevotella intermedia* can degrade neutrophil extracellular traps. *Mol. Oral Microbiol.* **2017**, *32*, 288–300. [[CrossRef](#)] [[PubMed](#)]
23. Wu, C.Y.; Liang, M.X.; Chen, Q. Production and stabilization of an integrin-binding moiety of complement component 3. *Mol. Biol.* **2015**, *49*, 723–727. [[CrossRef](#)]
24. Lukacs, S.; Nagy-Balo, Z.; Erdei, A.; Sandor, N.; Bajtaj, Z. The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. *Immunol. Lett.* **2017**, *189*, 64–72. [[CrossRef](#)] [[PubMed](#)]
25. Zhang, X.; Bajic, G.; Andersen, G.R.; Christiansen, S.H.; Vorup-Jensen, T. The cationic peptide LL-37 binds Mac-1 (CD11b/CD18) with a low dissociation rate and promotes phagocytosis. *Biochim. Biophys. Acta Proteins Proteom.* **2016**, *1864*, 471–478. [[CrossRef](#)] [[PubMed](#)]
26. Podolnikova, N.P.; Podolnikov, A.V.; Haas, T.A.; Lishko, V.K.; Ugarova, T.P. Ligand recognition specificity of leukocyte integrin $\alpha M\beta 2$ (Mac-1, CD11b/CD18) and its functional consequences. *Biochemistry* **2015**, *54*, 1408–1420. [[CrossRef](#)] [[PubMed](#)]
27. Lishko, V.K.; Moreno, B.; Podolnikova, N.P.; Ugarova, T.P. Identification of Human Cathelicidin Peptide LL-37 as a Ligand for Macrophage Integrin $\alpha M\beta 2$ (Mac-1, CD11b/CD18) that Promotes Phagocytosis by Opsonizing Bacteria. *Res. Rep. Biochem.* **2016**, *2016*, 39–55. [[PubMed](#)]
28. Hase, K.; Murakami, M.; Iimura, M.; Cole, S.P.; Horibe, Y.; Ohtake, T.; Obonyo, M.; Gallo, R.L.; Eckmann, L.; Kagnoff, M.F. Expression of LL-37 by Human Gastric Epithelial Cells as a Potential Host Defense Mechanism Against *Helicobacter pylori*. *Gastroenterology* **2003**, *125*, 1613–1625. [[CrossRef](#)] [[PubMed](#)]
29. Dürr, U.H.N.; Sudheendra, U.S.; Ramamoorthy, A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim. Biophys. Acta Biomembr.* **2006**, *1758*, 1408–1425. [[CrossRef](#)] [[PubMed](#)]
30. Maugeri, N.; Campana, L.; Gavina, M.; Covino, C.; de Metrio, M.; Panciroli, C.; Maiuri, L.; Maseri, A.; D'Angelo, A.; Bianchi, M.E.; et al. Activated platelets present high mobility group box 1 to neutrophils,

- inducing autophagy and promoting the extrusion of neutrophil extracellular traps. *J. Thromb. Haemost.* **2014**, *12*, 2074–2088. [[CrossRef](#)] [[PubMed](#)]
31. Yang, M.; Li, Y.; Chilukuri, K.; Brady, O.A.; Boulos, M.I.; Kappes, J.C.; Galileo, D.S. L1 stimulation of human glioma cell motility correlates with FAK activation. *J. Neurooncol.* **2011**, *105*, 27–44. [[CrossRef](#)] [[PubMed](#)]
 32. Burgett, M.E.; Lathia, J.D.; Roth, P.; Nowacki, A.S.; Galileo, D.S.; Pugacheva, E.; Huang, P.; Vasani, A.; Li, M.; Byzova, T.; et al. Direct contact with perivascular tumor cells enhances integrin $\alpha v \beta 3$ signaling and migration of endothelial cells. *Oncotarget* **2016**, *7*, 43852–43867. [[CrossRef](#)] [[PubMed](#)]
 33. Sundd, P.; Pospieszalska, M.K.; Ley, K. Neutrophil rolling at high shear: Flattening, catch bond behavior, tethers and slings. *Mol. Immunol.* **2013**, *55*, 59–69. [[CrossRef](#)] [[PubMed](#)]
 34. Montresor, A.; Toffali, L.; Constantin, G.; Laudanna, C. Chemokines and the signaling modules regulating integrin affinity. *Front. Immunol.* **2012**, *3*, 127. [[CrossRef](#)] [[PubMed](#)]
 35. Xu, S.; Wang, J.; Wang, J.-H.; Springer, T.A. Distinct recognition of complement iC3b by integrins $\alpha X \beta 2$ and $\alpha M \beta 2$. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 3403–3408. [[CrossRef](#)] [[PubMed](#)]
 36. Kazzaz, N.M.; Sule, G.; Knight, J.S. Intercellular Interactions as Regulators of NETosis. *Front. Immunol.* **2016**, *7*, 453. [[CrossRef](#)] [[PubMed](#)]
 37. Delgado-Rizo, V.; Martínez-Guzmán, M.A.; Iñiguez-Gutierrez, L.; García-Orozco, A.; Alvarado-Navarro, A.; Fafutis-Morris, M. Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview. *Front. Immunol.* **2017**, *8*, 1–20. [[CrossRef](#)] [[PubMed](#)]
 38. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.; Bianchi, M.E.; Nawroth, P.P.; et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. *EMBO J.* **2007**, *26*, 1129–1139. [[CrossRef](#)] [[PubMed](#)]
 39. Gillenius, E.; Urban, C.F. The adhesive protein invasins of *Yersinia pseudotuberculosis* induces neutrophil extracellular traps via $\beta 1$ integrins. *Microbes Infect.* **2015**, *17*, 327–336. [[CrossRef](#)] [[PubMed](#)]
 40. Monti, M.; Iommelli, F.; de Rosa, V.; Carriero, M.V.; Miceli, R.; Camerlingo, R.; di Minno, G.; del Vecchio, S. Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells. *PLoS ONE* **2017**, *12*, 1–15. [[CrossRef](#)] [[PubMed](#)]
 41. Mora, J.R.; Bono, M.R.; Manjunath, N.; Weninger, W.; Cavanagh, L.L.; Roseblatt, M.; Von Andrian, U.H. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. *Nature* **2003**, *424*, 88–93. [[CrossRef](#)] [[PubMed](#)]
 42. Caldwell, J.M.; Collins, M.H.; Kemme, K.A.; Sherrill, J.D.; Wen, T.; Rochman, M.; Stucke, E.M.; Amin, L.; Tai, H.; Putnam, P.E.; et al. Cadherin 26 is an α integrin-binding epithelial receptor regulated during allergic inflammation. *Mucosal Immunol.* **2017**, *10*, 1190–1201. [[CrossRef](#)] [[PubMed](#)]
 43. Dvorak, C.C. Musical chairs: In utero HCT via mobilization. *Blood* **2016**, *128*, 2378–2380. [[CrossRef](#)] [[PubMed](#)]
 44. Kim, A.G.; Vrecenak, J.D.; Boelig, M.M.; Eissenberg, L.; Rettig, M.P.; Riley, J.S.; Holt, M.S.; Conner, M.A.; Loukogeorgakis, S.P.; Li, H.; et al. Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by $\alpha 4 \beta 1 / 7$ inhibition. *Blood* **2016**, *128*, 2457–2461. [[CrossRef](#)] [[PubMed](#)]
 45. Allen, T.A.; Gracieux, D.; Talib, M.; Tokarz, D.A.; Hensley, M.T.; Cores, J.; Vandergriff, A.; Tang, J.; de Andrade, J.B.; Dinh, P.U.; et al. Angiopeliosis as an Alternative Mechanism of Cell Extravasation. *Stem Cells* **2017**, *35*, 170–180. [[CrossRef](#)] [[PubMed](#)]
 46. Kiefel, H.; Pfeifer, M.; Bondong, S.; Hazin, J.; Altevogt, P. Linking L1CAM-mediated signaling to NF- κ B activation. *Trends Mol. Med.* **2011**, *17*, 178–187. [[CrossRef](#)] [[PubMed](#)]
 47. Voura, E.B.; Ramjeesingh, R.A.; Montgomery, A.M.; Siu, C.H. Involvement of integrin $\alpha v \beta 3$ and cell adhesion molecule L1 in transendothelial migration of melanoma cells. *Mol. Biol. Cell* **2001**, *12*, 2699–2710. [[CrossRef](#)] [[PubMed](#)]
 48. Montgomery, A.M.; Becker, J.C.; Siu, C.H.; Lemmon, V.P.; Cheresch, D.A.; Pancook, J.D.; Zhao, X.; Reisfeld, R.A. Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin $\alpha v \beta 3$. *J. Cell Biol.* **1996**, *132*, 475–485. [[CrossRef](#)] [[PubMed](#)]
 49. Spring, F.A.; Griffiths, R.E.; Mankelov, T.J.; Agnew, C.; Parsons, S.F.; Chasis, J.A.; Anstee, D.J. Tetraspanins CD81 and CD82 facilitate $\alpha 4 \beta 1$ -mediated adhesion of human erythroblasts to vascular cell adhesion molecule-1. *PLoS ONE* **2013**, *8*, e62654. [[CrossRef](#)] [[PubMed](#)]
 50. Holmes, E.C. What does virus evolution tell us about virus origins? *J. Virol.* **2011**, *85*, 5247–5251. [[CrossRef](#)] [[PubMed](#)]

51. Stupack, D.G.; Cheresch, D.A. ECM remodeling regulates angiogenesis: Endothelial integrins look for new ligands. *Sci. STKE* **2002**, *2002*, PE7. [[CrossRef](#)] [[PubMed](#)]
52. Sheppard, D. Airway epithelial integrins: Why so many? *Am. J. Respir. Cell Mol. Biol.* **1998**, *19*, 349–351. [[CrossRef](#)] [[PubMed](#)]
53. Stewart, P.L.; Nemerow, G.R. Cell integrins: Commonly used receptors for diverse viral pathogens. *Trends Microbiol.* **2007**, *15*, 500–507. [[CrossRef](#)] [[PubMed](#)]
54. Hussein, H.A.; Walker, L.R.; Abdel-Raouf, U.M.; Desouky, S.A.; Montasser, A.K.; Akula, S.M. Beyond RGD: Virus interactions with integrins. *Arch. Virol.* **2015**, *160*, 2669–2681. [[CrossRef](#)] [[PubMed](#)]
55. La Linn, M.; Eble, J.A.; Lübken, C.; Slade, R.W.; Heino, J.; Davies, J.; Suhrbier, A. An arthritogenic α virus uses the $\alpha 1\beta 1$ integrin collagen receptor. *Virology* **2005**, *336*, 229–239. [[CrossRef](#)] [[PubMed](#)]
56. Xing, L.; Huhtala, M.; Pietiainen, V.; Kapyla, J.; Vuorinen, K.; Marjomaki, V.; Heino, J.; Johnson, M.S.; Hyypia, T.; Cheng, R.H. Structural and functional analysis of integrin $\alpha 2I$ domain interaction with echovirus 1. *J. Biol. Chem.* **2004**, *279*, 11632–11638. [[CrossRef](#)] [[PubMed](#)]
57. Marjomaki, V.; Turkki, P.; Huttunen, M. Infectious Entry Pathway of Enterovirus B Species. *Viruses* **2015**, *7*, 6387–6399. [[CrossRef](#)] [[PubMed](#)]
58. Feire, A.L.; Roy, R.M.; Manley, K.; Compton, T. The glycoprotein B disintegrin-like domain binds $\beta 1$ integrin to mediate cytomegalovirus entry. *J. Virol.* **2010**, *84*, 10026–10037. [[CrossRef](#)] [[PubMed](#)]
59. Graham, K.L.; Takada, Y.; Coulson, B.S. Rotavirus spike protein VP5* binds $\alpha 2\beta 1$ integrin on the cell surface and competes with virus for cell binding and infectivity. *J. Gen. Virol.* **2006**, *87*, 1275–1283. [[CrossRef](#)] [[PubMed](#)]
60. Coulson, B.S.; Londrigan, S.L.; Lee, D.J. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 5389–5394. [[CrossRef](#)] [[PubMed](#)]
61. Akula, S.M.; Pramod, N.P.; Wang, F.Z.; Chandran, B. Integrin $\alpha 3\beta 1$ (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. *Cell* **2002**, *108*, 407–419. [[CrossRef](#)]
62. Salone, B.; Martina, Y.; Piersanti, S.; Cundari, E.; Cherubini, G.; Franqueville, L.; Failla, C.M.; Boulanger, P.; Saggio, I. Integrin $\alpha 3\beta 1$ is an alternative cellular receptor for adenovirus serotype 5. *J. Virol.* **2003**, *77*, 13448–13454. [[CrossRef](#)] [[PubMed](#)]
63. Delgui, L.; Ona, A.; Gutierrez, S.; Luque, D.; Navarro, A.; Caston, J.R.; Rodriguez, J.F. The capsid protein of infectious bursal disease virus contains a functional $\alpha 4\beta 1$ integrin ligand motif. *Virology* **2009**, *386*, 360–372. [[CrossRef](#)] [[PubMed](#)]
64. Jackson, T.; Blakemore, W.; Newman, J.W.; Knowles, N.J.; Mould, A.P.; Humphries, M.J.; King, A.M. Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin $\alpha 5\beta 1$: Influence of the leucine residue within the RGD motif on selectivity of integrin binding. *J. Gen. Virol.* **2000**, *81*, 1383–1391. [[CrossRef](#)] [[PubMed](#)]
65. Tugizov, S.M.; Berline, J.W.; Palefsky, J.M. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. *Nat. Med.* **2003**, *9*, 307–314. [[CrossRef](#)] [[PubMed](#)]
66. Davison, E.; Diaz, R.M.; Hart, I.R.; Santis, G.; Marshall, J.F. Integrin $\alpha 5\beta 1$ -mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. *J. Virol.* **1997**, *71*, 6204–6207. [[PubMed](#)]
67. Walker, L.R.; Hussein, H.A.M.; Akula, S.M. Disintegrin-like domain of glycoprotein B regulates Kaposi's sarcoma-associated herpesvirus infection of cells. *J. Gen. Virol.* **2014**, *95*, 1770–1782. [[CrossRef](#)] [[PubMed](#)]
68. Huang, S.; Kamata, T.; Takada, Y.; Ruggeri, Z.M.; Nemerow, G.R. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. *J. Virol.* **1996**, *70*, 4502–4508. [[PubMed](#)]
69. Stanway, G.; Kalkkinen, N.; Roivainen, M.; Ghazi, F.; Khan, M.; Smyth, M.; Meurman, O.; Hyypia, T. Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group. *J. Virol.* **1994**, *68*, 8232–8238. [[PubMed](#)]
70. Pulli, T.; Koivunen, E.; Hyypia, T. Cell-surface interactions of echovirus 22. *J. Biol. Chem.* **1997**, *272*, 21176–21180. [[CrossRef](#)] [[PubMed](#)]
71. Li, E.; Brown, S.L.; Stupack, D.G.; Puente, X.S.; Cheresch, D.A.; Nemerow, G.R. Integrin $\alpha v\beta 1$ is an adenovirus coreceptor. *J. Virol.* **2001**, *75*, 5405–5409. [[CrossRef](#)] [[PubMed](#)]

72. Nelsen-Salz, B.; Eggers, H.J.; Zimmermann, H. Integrin $\alpha\beta 3$ (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty. *J. Gen. Virol.* **1999**, *80*, 2311–2313. [[CrossRef](#)] [[PubMed](#)]
73. Roivainen, M.; Piirainen, L.; Hovi, T.; Virtanen, I.; Riikonen, T.; Heino, J.; Hyypia, T. Entry of coxsackievirus A9 into host cells: Specific interactions with $\alpha\beta 3$ integrin, the vitronectin receptor. *Virology* **1994**, *203*, 357–365. [[CrossRef](#)] [[PubMed](#)]
74. Neff, S.; Sa-Carvalho, D.; Rieder, E.; Mason, P.W.; Blystone, S.D.; Brown, E.J.; Baxt, B. Foot-and-mouth disease virus virulent for cattle utilizes the integrin $\alpha\beta 3$ as its receptor. *J. Virol.* **1998**, *72*, 3587–3594. [[PubMed](#)]
75. Fan, W.; Qian, P.; Wang, D.; Zhi, X.; Wei, Y.; Chen, H.; Li, X. Integrin $\alpha\beta 3$ promotes infection by Japanese encephalitis virus. *Res. Vet. Sci.* **2017**, *111*, 67–74. [[CrossRef](#)] [[PubMed](#)]
76. Garrigues, H.J.; Rubinchikova, Y.E.; Dipersio, C.M.; Rose, T.M. Integrin $\alpha V\beta 3$ Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. *J. Virol.* **2008**, *82*, 1570–1580. [[CrossRef](#)] [[PubMed](#)]
77. Matthys, V.S.; Gorbunova, E.E.; Gavrilovskaya, I.N.; Mackow, E.R. Andes virus recognition of human and Syrian hamster $\beta 3$ integrins is determined by an L33P substitution in the PSI domain. *J. Virol.* **2010**, *84*, 352–360. [[CrossRef](#)] [[PubMed](#)]
78. Wickham, T.J.; Mathias, P.; Cheresch, D.A.; Nemerow, G.R. Integrins $\alpha\beta 3$ and $\alpha\beta 5$ promote adenovirus internalization but not virus attachment. *Cell* **1993**, *73*, 309–319. [[CrossRef](#)]
79. Zarate, S.; Romero, P.; Espinosa, R.; Arias, C.F.; Lopez, S. VP7 mediates the interaction of rotaviruses with integrin $\alpha\beta 3$ through a novel integrin-binding site. *J. Virol.* **2004**, *78*, 10839–10847. [[CrossRef](#)] [[PubMed](#)]
80. Guerrero, C.A.; Mendez, E.; Zarate, S.; Isa, P.; Lopez, S.; Arias, C.F. Integrin $\alpha\beta 3$ mediates rotavirus cell entry. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 14644–14649. [[CrossRef](#)] [[PubMed](#)]
81. Gavrilovskaya, I.N.; Shepley, M.; Shaw, R.; Ginsberg, M.H.; Mackow, E.R. $\beta 3$ Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 7074–7079. [[CrossRef](#)] [[PubMed](#)]
82. Veettil, M.V.; Sadagopan, S.; Sharma-Walia, N.; Wang, F.Z.; Raghu, H.; Varga, L.; Chandran, B. Kaposi's Sarcoma-Associated Herpesvirus Forms a Multimolecular Complex of Integrins (V5, V3, and 31) and CD98-xCT during Infection of Human Dermal Microvascular Endothelial Cells, and CD98-xCT Is Essential for the Postentry Stage of Infection. *J. Virol.* **2008**, *82*, 12126–12144. [[CrossRef](#)] [[PubMed](#)]
83. Chesnokova, L.S.; Hutt-Fletcher, L.M. Fusion of Epstein-Barr virus with epithelial cells can be triggered by $\alpha\beta 5$ in addition to $\alpha\beta 6$ and $\alpha\beta 8$, and integrin binding triggers a conformational change in glycoproteins gH/gL. *J. Virol.* **2011**, *85*, 13214–13223. [[CrossRef](#)] [[PubMed](#)]
84. Burman, A.; Clark, S.; Abrescia, N.G.; Fry, E.E.; Stuart, D.I.; Jackson, T. Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for αv integrins. *J. Virol.* **2006**, *80*, 9798–9810. [[CrossRef](#)] [[PubMed](#)]
85. Berryman, S.; Clark, S.; Monaghan, P.; Jackson, T. Early events in integrin $\alpha\beta 6$ -mediated cell entry of foot-and-mouth disease virus. *J. Virol.* **2005**, *79*, 8519–8534. [[CrossRef](#)] [[PubMed](#)]
86. Gianni, T.; Salvioli, S.; Chesnokova, L.S.; Hutt-Fletcher, L.M.; Campadelli-Fiume, G. $\alpha\beta 6$ - and $\alpha\beta 8$ -integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion. *PLoS Pathog.* **2013**, *9*, e1003806. [[CrossRef](#)] [[PubMed](#)]
87. Zell, R. Picornaviridae-the ever-growing virus family. *Arch. Virol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
88. Tuthill, T.J.; Groppelli, E.; Hogle, J.M.; Rowlands, D.J. Picornaviruses. *Curr. Top. Microbiol. Immunol.* **2010**, *343*, 43–89. [[PubMed](#)]
89. Johnson, M.S.; Lu, N.; Denessiouk, K.; Heino, J.; Gullberg, D. Integrins during evolution: Evolutionary trees and model organisms. *Biochim. Biophys. Acta* **2009**, *1788*, 779–789. [[CrossRef](#)] [[PubMed](#)]
90. Emsley, J.; Knight, C.G.; Farndale, R.W.; Barnes, M.J.; Liddington, R.C. Structural basis of collagen recognition by integrin $\alpha 2\beta 1$. *Cell* **2000**, *101*, 47–56. [[CrossRef](#)]
91. Wary, K.K.; Mariotti, A.; Zurzolo, C.; Giancotti, F.G. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. *Cell* **1998**, *94*, 625–634. [[CrossRef](#)]
92. Pietiainen, V.; Marjomaki, V.; Upla, P.; Pelkmans, L.; Helenius, A.; Hyypia, T. Echovirus 1 endocytosis into caveosomes requires lipid rafts, dynamin II, and signaling events. *Mol. Biol. Cell* **2004**, *15*, 4911–4925. [[CrossRef](#)] [[PubMed](#)]
93. Parton, R.G. Caveolae and caveolins. *Curr. Opin. Cell Biol.* **1996**, *8*, 542–548. [[CrossRef](#)]

94. Marjomaki, V.; Pietiainen, V.; Matilainen, H.; Upla, P.; Ivaska, J.; Nissinen, L.; Reunanen, H.; Huttunen, P.; Hyypia, T.; Heino, J. Internalization of echovirus 1 in caveolae. *J. Virol.* **2002**, *76*, 1856–1865. [[CrossRef](#)] [[PubMed](#)]
95. Bergelson, J.M.; Cunningham, J.A.; Droguett, G.; Kurt-Jones, E.A.; Krithivas, A.; Hong, J.S.; Horwitz, M.S.; Crowell, R.L.; Finberg, R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* **1997**, *275*, 1320–1323. [[CrossRef](#)] [[PubMed](#)]
96. Huang, Y.J.S.; Higgs, S.; Horne, K.M.E.; Vanlandingham, D.L. Flavivirus-Mosquito interactions. *Viruses* **2014**, *6*, 4703–4730. [[CrossRef](#)] [[PubMed](#)]
97. Unni, S.K.; Růžek, D.; Chhatbar, C.; Mishra, R.; Johri, M.K.; Singh, S.K. Japanese encephalitis virus: From genome to infectome. *Microbes Infect.* **2011**, *13*, 312–321. [[CrossRef](#)] [[PubMed](#)]
98. Luca, V.C.; AbiMansour, J.; Nelson, C.A.; Fremont, D.H. Crystal Structure of the Japanese Encephalitis Virus Envelope Protein. *J. Virol.* **2012**, *86*, 2337–2346. [[CrossRef](#)] [[PubMed](#)]
99. Das, S.; Laxminarayana, S.V.; Chandra, N.; Ravi, V.; Desai, A. Heat shock protein 70 on Neuro2a cells is a putative receptor for Japanese encephalitis virus. *Virology* **2009**, *385*, 47–57. [[CrossRef](#)] [[PubMed](#)]
100. Chu, J.J.; Rajamanonmani, R.; Li, J.; Bhuvanankantham, R.; Lescar, J.; Ng, M.L. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. *J. Gen. Virol.* **2005**, *86*, 405–412. [[CrossRef](#)] [[PubMed](#)]
101. Chu, J.J.H.; Ng, M.L. Interaction of West Nile virus with $\alpha V\beta 3$ integrin mediates virus entry into cells. *J. Biol. Chem.* **2004**, *279*, 54533–54541. [[CrossRef](#)] [[PubMed](#)]
102. Bogachek, M.V.; Zaitsev, B.N.; Sekatskii, S.K.; Protopopova, E.V.; Ternovoi, V.A.; Ivanova, A.V.; Kachko, A.V.; Ivanisenko, V.A.; Dietler, G.; Loktev, V.B. Characterization of glycoprotein E C-end of West Nile virus and evaluation of its interaction force with $\alpha V\beta 3$ integrin as putative cellular receptor. *Biochemistry* **2010**, *75*, 472–480. [[CrossRef](#)] [[PubMed](#)]
103. Lee, E.; Lobigs, M. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. *J. Virol.* **2000**, *74*, 8867–8875. [[CrossRef](#)] [[PubMed](#)]
104. Wan, S.-W.; Lin, C.-F.; Lu, Y.-T.; Lei, H.-Y.; Anderson, R.; Lin, Y.-S. Endothelial cell surface expression of protein disulfide isomerase activates $\beta 1$ and $\beta 3$ integrins and facilitates dengue virus infection. *J. Cell. Biochem.* **2012**, *113*, 1681–1691. [[CrossRef](#)] [[PubMed](#)]
105. van der Most, R.G.; Corver, J.; Strauss, J.H. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. *Virology* **1999**, *265*, 83–95. [[CrossRef](#)] [[PubMed](#)]
106. Feire, A.L.; Koss, H.; Compton, T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 15470–15475. [[CrossRef](#)] [[PubMed](#)]
107. Assuncao-Miranda, I.; Cruz-Oliveira, C.; Da Poian, A.T. Molecular mechanisms involved in the pathogenesis of α virus-induced arthritis. *BioMed Res. Int.* **2013**, *2013*, 973516. [[CrossRef](#)] [[PubMed](#)]
108. Mangel, W.F.; San Martin, C. Structure, function and dynamics in adenovirus maturation. *Viruses* **2014**, *6*, 4536–4570. [[CrossRef](#)] [[PubMed](#)]
109. Nemerow, G.R.; Stewart, P.L. Role of αv integrins in adenovirus cell entry and gene delivery. *Microbiol. Mol. Biol. Rev. MMBR* **1999**, *63*, 725–734. [[PubMed](#)]
110. Wickham, T.J.; Filardo, E.J.; Cheresch, D.A.; Nemerow, G.R. Integrin $\alpha v\beta 5$ selectively promotes adenovirus mediated cell membrane permeabilization. *J. Cell Biol.* **1994**, *127*, 257–264. [[CrossRef](#)] [[PubMed](#)]
111. Wickham, T.J. Targeting adenovirus. *Gene Ther.* **2000**, *7*, 110–114. [[CrossRef](#)] [[PubMed](#)]
112. Bai, M.; Harfe, B.; Freimuth, P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. *J. Virol.* **1993**, *67*, 5198–5205. [[PubMed](#)]
113. Miyamoto, S.; Akiyama, S.K.; Yamada, K.M. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. *Science* **1995**, *267*, 883–885. [[CrossRef](#)] [[PubMed](#)]
114. Li, E.; Stupack, D.; Klemke, R.; Cheresch, D.A.; Nemerow, G.R. Adenovirus endocytosis via αv integrins requires phosphoinositide-3-OH kinase. *J. Virol.* **1998**, *72*, 2055–2061. [[PubMed](#)]
115. Li, E.; Stupack, D.; Bokoch, G.M.; Nemerow, G.R. Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. *J. Virol.* **1998**, *72*, 8806–8812. [[PubMed](#)]

116. Schmaljohn, C.; Hjelle, B. Hantaviruses: A global disease problem. *Emerg. Infect. Dis.* **1997**, *3*, 95–104. [[CrossRef](#)] [[PubMed](#)]
117. Bondu, V.; Wu, C.; Cao, W.; Simons, P.C.; Gillette, J.; Zhu, J.; Erb, L.; Zhang, X.F.; Buranda, T. Low-affinity binding in cis to P2Y2R mediates force-dependent integrin activation during hantavirus infection. *Mol. Biol. Cell* **2017**, *28*, 2887–2903. [[CrossRef](#)] [[PubMed](#)]
118. Gavrilovskaya, I.N.; Peresleni, T.; Geimonen, E.; Mackow, E.R. Pathogenic hantaviruses selectively inhibit $\beta 3$ integrin directed endothelial cell migration. *Arch. Virol.* **2002**, *147*, 1913–1931. [[CrossRef](#)] [[PubMed](#)]
119. Gavrilovskaya, I.N.; Gorbunova, E.E.; Mackow, N.A.; Mackow, E.R. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. *J. Virol.* **2008**, *82*, 5797–5806. [[CrossRef](#)] [[PubMed](#)]
120. Bottcher, B.; Kiselev, N.A.; Stel'Mashchuk, V.Y.; Perevozchikova, N.A.; Borisov, A.V.; Crowther, R.A. Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy. *J. Virol.* **1997**, *71*, 325–330. [[PubMed](#)]
121. Ye, C.; Han, X.; Yu, Z.; Zhang, E.; Wang, L.; Liu, H. Infectious Bursal Disease Virus Activates c-Src To Promote $\alpha 4\beta 1$ Integrin-Dependent Viral Entry by Modulating the Downstream Akt-RhoA GTPase-Actin Rearrangement Cascade. *J. Virol.* **2017**, *91*. [[CrossRef](#)] [[PubMed](#)]
122. Tate, J.E.; Burton, A.H.; Boschi-Pinto, C.; Parashar, U.D. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000–2013. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **2016**, *62*, S96–S105. [[CrossRef](#)] [[PubMed](#)]
123. Yeager, M.; Dryden, K.A.; Olson, N.H.; Greenberg, H.B.; Baker, T.S. Three-dimensional structure of rhesus rotavirus by cryoelectron microscopy and image reconstruction. *J. Cell Biol.* **1990**, *110*, 2133–2144. [[CrossRef](#)] [[PubMed](#)]
124. Maginnis, M.S.; Forrest, J.C.; Kopecky-Bromberg, S.A.; Dickeson, S.K.; Santoro, S.A.; Zutter, M.M.; Nemerow, G.R.; Bergelson, J.M.; Dermody, T.S. B1 integrin mediates internalization of mammalian reovirus. *J. Virol.* **2006**, *80*, 2760–2770. [[CrossRef](#)] [[PubMed](#)]
125. Marcinkiewicz, C. Applications of snake venom components to modulate integrin activities in cell-matrix interactions. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 1974–1986. [[CrossRef](#)] [[PubMed](#)]
126. Huang, T.-F.; Hsu, C.-C.; Kuo, Y.-J. Anti-thrombotic agents derived from snake venom proteins. *Thromb. J.* **2016**, *14*, 18. [[CrossRef](#)] [[PubMed](#)]
127. Musial, J.; Niewiarowski, S.; Rucinski, B.; Stewart, G.J.; Cook, J.J.; Williams, J.A.; Edmunds, L.H., Jr. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. *Circulation* **1990**, *82*, 261–273. [[CrossRef](#)] [[PubMed](#)]
128. Walsh, E.M.; Marcinkiewicz, C. Non-RGD-containing snake venom disintegrins, functional and structural relations. *Toxicon* **2011**, *58*, 355–362. [[CrossRef](#)] [[PubMed](#)]
129. Calvete, J.J. The continuing saga of snake venom disintegrins. *Toxicon* **2013**, *62*, 40–49. [[CrossRef](#)] [[PubMed](#)]
130. Marcinkiewicz, C.; Lobb, R.R.; Marcinkiewicz, M.M.; Daniel, J.L.; Smith, J.B.; Dangelmaier, C.; Weinreb, P.H.; Beacham, D.A.; Niewiarowski, S. Isolation and characterization of EMS16, a C-lectin type protein from *Echis multisquamatus* venom, a potent and selective inhibitor of the $\alpha 2\beta 1$ integrin. *Biochemistry* **2000**, *39*, 9859–9867. [[CrossRef](#)] [[PubMed](#)]
131. Horii, K.; Okuda, D.; Morita, T.; Mizuno, H. Crystal structure of EMS16 in complex with the integrin $\alpha 2$ -I domain. *J. Mol. Biol.* **2004**, *341*, 519–527. [[CrossRef](#)] [[PubMed](#)]
132. Hutchings, H.; Ortega, N.; Plouet, J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. *FASEB J.* **2003**, *17*, 1520–1522. [[CrossRef](#)] [[PubMed](#)]
133. Eble, J.A.; Bruckner, P.; Mayer, U. Vipera lebetina venom contains two disintegrins inhibiting laminin-binding $\beta 1$ integrins. *J. Biol. Chem.* **2003**, *278*, 26488–26496. [[CrossRef](#)] [[PubMed](#)]
134. Sato, R.; Yamasaki, M.; Hirai, K.; Matsubara, T.; Nomura, T.; Sato, F.; Mimata, H. Angiopoietin-like protein 2 induces androgen-independent and malignant behavior in human prostate cancer cells. *Oncol. Rep.* **2015**, *33*, 58–66. [[CrossRef](#)] [[PubMed](#)]
135. Yugami, M.; Odagiri, H.; Endo, M.; Tsutsuki, H.; Fujii, S.; Kadomatsu, T.; Masuda, T.; Miyata, K.; Terada, K.; Tanoue, H.; et al. Mice Deficient in Angiopoietin-like Protein 2 (Angptl2) Gene Show Increased Susceptibility

- to Bacterial Infection Due to Attenuated Macrophage Activity. *J. Biol. Chem.* **2016**, *291*, 18843–18852. [[CrossRef](#)] [[PubMed](#)]
136. Vlahakis, N.E.; Young, B.A.; Atakilit, A.; Hawkridge, A.E.; Issaka, R.B.; Boudreau, N.; Sheppard, D. Integrin $\alpha 9 \beta 1$ directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. *J. Biol. Chem.* **2007**, *282*, 15187–15196. [[CrossRef](#)] [[PubMed](#)]
137. Lin, H.Y.; Lansing, L.; Merillon, J.M.; Davis, F.B.; Tang, H.Y.; Shih, A.; Vitrac, X.; Krisa, S.; Keating, T.; Cao, H.J.; et al. Integrin $\alpha V \beta 3$ contains a receptor site for resveratrol. *FASEB J.* **2006**, *20*, 1742–1744. [[CrossRef](#)] [[PubMed](#)]
138. Lin, H.-Y.; Tang, H.-Y.; Keating, T.; Wu, Y.-H.; Shih, A.; Hammond, D.; Sun, M.; Hercbergs, A.; Davis, F.B.; Davis, P.J. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: Both actions are integrin and ERK mediated. *Carcinogenesis* **2008**, *29*, 62–69. [[CrossRef](#)] [[PubMed](#)]
139. Belleri, M.; Ribatti, D.; Savio, M.; Stivala, L.A.; Forti, L.; Tanghetti, E.; Alessi, P.; Coltrini, D.; Bugatti, A.; Mitola, S.; et al. $\alpha V \beta 3$ Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. *Mol. Cancer Ther.* **2008**, *7*, 3761–3770. [[CrossRef](#)] [[PubMed](#)]
140. Lin, H.Y.; Cody, V.; Davis, F.B.; Hercbergs, A.A.; Luidens, M.K.; Mousa, S.A.; Davis, P.J. Identification and functions of the plasma membrane receptor for thyroid hormone analogues. *Discov. Med.* **2011**, *11*, 337–347. [[PubMed](#)]
141. Cayrol, F.; Flaqué, M.C.D.; Fernando, T.; Yang, S.N.; Sterle, H.A.; Bolontrade, M.; Amorós, M.; Isse, B.; Fariás, R.N.; Ahn, H.; et al. Integrin $\alpha V \beta 3$ acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. *Blood* **2015**, *125*, 841–851. [[CrossRef](#)] [[PubMed](#)]
142. Bergh, J.J.; Lin, H.Y.; Lansing, L.; Mohamed, S.N.; Davis, F.B.; Mousa, S.; Davis, P.J. Integrin $\alpha V \beta 3$ contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. *Endocrinology* **2005**, *146*, 2864–2871. [[CrossRef](#)] [[PubMed](#)]
143. Lin, H.Y.; Sun, M.; Lin, C.; Tang, H.Y.; London, D.; Shih, A.; Davis, F.B.; Davis, P.J. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor- α -positive and -negative breast cancer cells. *J. Steroid Biochem. Mol. Biol.* **2009**, *113*, 182–188. [[CrossRef](#)] [[PubMed](#)]
144. Chin, Y.-T.; Yang, S.-H.; Chang, T.-C.; Changou, C.A.; Lai, H.-Y.; Fu, E.; Huangfu, W.-C.; Davis, P.J.; Lin, H.-Y.; Liu, L.F. Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ER α status. *Oncotarget* **2015**, *6*, 35866–35879. [[CrossRef](#)] [[PubMed](#)]
145. Lin, Y.; Rao, J.; Zha, X.L.; Xu, H. Angiotensin-like 3 induces podocyte f-actin rearrangement through integrin $\alpha v \beta 3$ /FAK/PI3K pathway-mediated rac1 Activation. *BioMed Res. Int.* **2013**. [[CrossRef](#)] [[PubMed](#)]
146. Gomez Perdiguero, E.; Liabotis-Fontugne, A.; Durand, M.I.; Faye, C.M.; Ricard-Blum, S.; Simonutti, M.; Augustin, S.B.; Robb, B.M.; Paques, M.; Valenzuela, D.M.; et al. ANGPTL4- $\alpha V \beta 3$ interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2. *J. Pathol.* **2016**, *240*, 461–471. [[CrossRef](#)] [[PubMed](#)]
147. Clement, L.C.; Macé, C.; Avila-Casado, C.; Joles, J.A.; Kersten, S.; Chugh, S.S. Circulating angiotensin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. *Nat. Med.* **2014**, *20*, 37–46. [[CrossRef](#)] [[PubMed](#)]
148. Worthington, J.J.; Klementowicz, J.E.; Travis, M.A. TGF β : A sleeping giant awoken by integrins. *Trends Biochem. Sci.* **2011**, *36*, 47–54. [[CrossRef](#)] [[PubMed](#)]
149. Dong, X.; Zhao, B.; Iacob, R.E.; Zhu, J.; Koksai, A.C.; Lu, C.; Engen, J.R.; Springer, T.A. Force interacts with macromolecular structure in activation of TGF- β . *Nature* **2017**, *542*, 55–59. [[CrossRef](#)] [[PubMed](#)]
150. Juárez, P.; Comas, I.; González-Candelas, F.; Calvete, J.J. Evolution of snake venom disintegrins by positive Darwinian selection. *Mol. Biol. Evol.* **2008**, *25*, 2391–2407. [[CrossRef](#)] [[PubMed](#)]
151. Souza, D.H.F.; Iemma, M.R.C.; Ferreira, L.L.; Faria, J.P.; Oliva, M.L.V.; Zingali, R.B.; Niewiarowski, S.; Selistre-de-Araujo, H.S. The Disintegrin-like Domain of the Snake Venom Metalloprotease Alternagin Inhibits $\alpha 2 \beta 1$ Integrin-Mediated Cell Adhesion. *Arch. Biochem. Biophys.* **2000**, *384*, 341–350. [[CrossRef](#)] [[PubMed](#)]
152. Kamiguti, A.S.; Hay, C.R.; Zuzel, M. Inhibition of collagen-induced platelet aggregation as the result of cleavage of $\alpha 2 \beta 1$ -integrin by the snake venom metalloproteinase jararhagin. *Biochem. J.* **1996**, *320*, 635–641. [[CrossRef](#)] [[PubMed](#)]

153. Jakubowski, P.; Calvete, J.J.; Eble, J.A.; Lazarovici, P.; Marcinkiewicz, C. Identification of inhibitors of $\alpha 2\beta 1$ integrin, members of C-lectin type proteins, in Echis sochureki venom. *Toxicol. Appl. Pharmacol.* **2013**, *269*, 34–42. [[CrossRef](#)] [[PubMed](#)]
154. Pilorget, A.; Conesa, M.; Sarray, S.; Michaud-Levesque, J.; Daoud, S.; Kim, K.S.; Demeule, M.; Marvaldi, J.; El Ayeb, M.; Marrakchi, N.; et al. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo. *J. Cell. Physiol.* **2007**, *211*, 307–315. [[CrossRef](#)] [[PubMed](#)]
155. Momic, T.; Cohen, G.; Reich, R.; Arlinghaus, F.T.; Eble, J.A.; Marcinkiewicz, C.; Lazarovici, P. Vixapatin (VP12), a C-type lectin-protein from Vipera xantina palestinae venom: Characterization as a novel anti-angiogenic compound. *Toxins* **2012**, *4*, 862–877. [[CrossRef](#)] [[PubMed](#)]
156. Rosenow, F.; Ossig, R.; Thormeyer, D.; Gasmann, P.; Schlüter, K.; Brunner, G.; Haier, J.; Eble, J.A. Antimetastatic Integrin as Inhibitors of Snake Venoms. *Neoplasia* **2008**, *10*, 168–176. [[CrossRef](#)] [[PubMed](#)]
157. Frankel, G.; Lider, O.; Hershkoviz, R.; Mould, A.P.; Kachalsky, S.G.; Candy, D.C.; Cahalon, L.; Humphries, M.J.; Dougan, G. The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to $\beta 1$ integrins. *J. Biol. Chem.* **1996**, *271*, 20359–20364. [[CrossRef](#)] [[PubMed](#)]
158. Watarai, M.; Funato, S.; Sasakawa, C. Interaction of Ipa proteins of Shigella flexneri with $\alpha 5\beta 1$ integrin promotes entry of the bacteria into mammalian cells. *J. Exp. Med.* **1996**, *183*, 991–999. [[CrossRef](#)] [[PubMed](#)]
159. Ishibashi, Y.; Claus, S.; Relman, D.A. Bordetella pertussis filamentous hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18). *J. Exp. Med.* **1994**, *180*, 1225–1233. [[CrossRef](#)] [[PubMed](#)]
160. Tilly, K.; Rosa, P.A.; Stewart, P.E. Biology of Infection with Borrelia burgdorferi. *Infect. Dis. Clin. N. Am.* **2008**, *22*, 217–234. [[CrossRef](#)] [[PubMed](#)]
161. Hyde, J.A. Borrelia burgdorferi Keeps Moving and Carries on: A Review of Borrelial Dissemination and Invasion. *Front. Immunol.* **2017**, *8*, 114. [[CrossRef](#)] [[PubMed](#)]
162. Caine, J.A.; Coburn, J. Multifunctional and Redundant Roles of Borrelia burgdorferi Outer Surface Proteins in Tissue Adhesion, Colonization, and Complement Evasion. *Front. Immunol.* **2016**, *7*, 442. [[CrossRef](#)] [[PubMed](#)]
163. Coburn, J.; Magoun, L.; Bodary, S.C.; Leong, J.M. Integrins $\alpha \nu \beta 3$ and $\alpha 5\beta 1$ mediate attachment of lyme disease spirochetes to human cells. *Infect. Immun.* **1998**, *66*, 1946–1952. [[PubMed](#)]
164. Coburn, J.; Leong, J.M.; Erban, J.K. Integrin α IIb β 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 7059–7063. [[CrossRef](#)] [[PubMed](#)]
165. Coburn, J.; Chege, W.; Magoun, L.; Bodary, S.C.; Leong, J.M. Characterization of a candidate Borrelia burgdorferi $\beta 3$ -chain integrin ligand identified using a phage display library. *Mol. Microbiol.* **1999**, *34*, 926–940. [[CrossRef](#)] [[PubMed](#)]
166. Defoe, G.; Coburn, J. Delineation of Borrelia burgdorferi p66 sequences required for integrin α IIb β 3 recognition. *Infect. Immun.* **2001**, *69*, 3455–3459. [[CrossRef](#)] [[PubMed](#)]
167. Ristow, L.C.; Bonde, M.; Lin, Y.P.; Sato, H.; Curtis, M.; Wesley, E.; Hahn, B.L.; Fang, J.; Wilcox, D.A.; Leong, J.M.; et al. Integrin binding by Borrelia burgdorferi P66 facilitates dissemination but is not required for infectivity. *Cell. Microbiol.* **2015**, *17*, 1021–1036. [[CrossRef](#)] [[PubMed](#)]
168. Kumar, D.; Ristow, L.C.; Shi, M.; Mukherjee, P.; Caine, J.A.; Lee, W.Y.; Kubes, P.; Coburn, J.; Chaconas, G. Intravital Imaging of Vascular Transmigration by the Lyme Spirochete: Requirement for the Integrin Binding Residues of the B. burgdorferi P66 Protein. *PLoS Pathog.* **2015**, *11*, 1–20. [[CrossRef](#)] [[PubMed](#)]
169. Wood, E.; Tamborero, S.; Mingarro, I.; Esteve-Gassent, M.D. BB0172, a Borrelia burgdorferi outer membrane protein that binds integrin $\alpha 3\beta 1$. *J. Bacteriol.* **2013**, *195*, 3320–3330. [[CrossRef](#)] [[PubMed](#)]
170. Behera, A.K.; Durand, E.; Cugini, C.; Antonara, S.; Bourassa, L.; Hildebrand, E.; Hu, L.T.; Coburn, J. Borrelia burgdorferi BBB07 interaction with integrin $\alpha 3\beta 1$ stimulates production of pro-inflammatory mediators in primary human chondrocytes. *Cell. Microbiol.* **2008**, *10*, 320–331. [[PubMed](#)]
171. Song, J.; Zhang, X.; Buscher, K.; Wang, Y.; Wang, H.; di Russo, J.; Li, L.; Lutke-Enking, S.; Zarbock, A.; Stadtmann, A.; et al. Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration. *Cell Rep.* **2017**, *18*, 1256–1269. [[CrossRef](#)] [[PubMed](#)]
172. Wroblewski, L.E.; Peek, R.M.; Wilson, K.T. Helicobacter pylori and gastric cancer: Factors that modulate disease risk. *Clin. Microbiol. Rev.* **2010**, *23*, 713–739. [[CrossRef](#)] [[PubMed](#)]

173. Saber, T.; Ghonaim, M.M.; Yousef, A.R.; Khalifa, A.; Al Qurashi, H.; Shaqhan, M.; Samaha, M. Association of *Helicobacter pylori* cagA Gene with Gastric Cancer and Peptic Ulcer in Saudi Patients. *J. Microbiol. Biotechnol.* **2015**, *25*, 1146–1153. [[CrossRef](#)] [[PubMed](#)]
174. Parsonnet, J.; Friedman, G.D.; Orentreich, N.; Vogelman, H. Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection. *Gut* **1997**, *40*, 297–301. [[CrossRef](#)] [[PubMed](#)]
175. Wallden, K.; Rivera-Calzada, A.; Waksman, G. Type IV secretion systems: Versatility and diversity in function. *Cell. Microbiol.* **2010**, *12*, 1203–1212. [[CrossRef](#)] [[PubMed](#)]
176. Terradot, L.; Waksman, G. Architecture of the *Helicobacter pylori* Cag-type IV secretion system. *FEBS J.* **2011**, *278*, 1213–1222. [[CrossRef](#)] [[PubMed](#)]
177. Conradi, J.; Tegtmeyer, N.; Woźna, M.; Wissbrock, M.; Michalek, C.; Gagell, C.; Cover, T.L.; Frank, R.; Sewald, N.; Backert, S. An RGD helper sequence in CagL of *Helicobacter pylori* assists in interactions with integrins and injection of CagA. *Front. Cell. Infect. Microbiol.* **2012**, *2*, 70. [[CrossRef](#)] [[PubMed](#)]
178. Wiedemann, T.; Hofbauer, S.; Tegtmeyer, N.; Huber, S.; Sewald, N.; Wessler, S.; Backert, S.; Rieder, G. *Helicobacter pylori* CagL dependent induction of gastrin expression via a novel v 5-integrin-integrin linked kinase signalling complex. *Gut* **2012**, *61*, 986–996. [[CrossRef](#)] [[PubMed](#)]
179. Kwok, T.; Zabler, D.; Urman, S.; Rohde, M.; Hartig, R.; Wessler, S.; Misselwitz, R.; Berger, J.; Sewald, N.; König, W.; et al. *Helicobacter* exploits integrin for type IV secretion and kinase activation. *Nature* **2007**, *449*, 862–866. [[CrossRef](#)] [[PubMed](#)]
180. Conradi, J.; Huber, S.; Gaus, K.; Mertink, F.; Royo Gracia, S.; Strijowski, U.; Backert, S.; Sewald, N. Cyclic RGD peptides interfere with binding of the *Helicobacter pylori* protein CagL to integrins $\alpha\beta3$ and $\alpha5\beta1$. *Amino Acids* **2012**, *43*, 219–232. [[CrossRef](#)] [[PubMed](#)]
181. Barden, S.; Niemann, H.H. Adhesion of several cell lines to *Helicobacter pylori* CagL is mediated by integrin $\alpha\beta6$ via an rgdxxl motif. *J. Mol. Biol.* **2015**, *427*, 1304–1315. [[CrossRef](#)] [[PubMed](#)]
182. Bönig, T.; Olbermann, P.; Bats, S.H.; Fischer, W.; Josenhans, C.; Blaser, M.J.; Atherton, J.C.; Kusters, J.G.; Vliet, A.H.V.; Kuipers, E.J.; et al. Systematic site-directed mutagenesis of the *Helicobacter pylori* CagL protein of the Cag type IV secretion system identifies novel functional domains. *Sci. Rep.* **2016**, *6*, 38101. [[CrossRef](#)] [[PubMed](#)]
183. Mueller, D.; Tegtmeyer, N.; Brandt, S.; Yamaoka, Y.; de Poire, E.; Sgouras, D.; Wessler, S.; Torres, J.; Smolka, A.; Backert, S. c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian *Helicobacter pylori* strains. *J. Clin. Investig.* **2012**, *122*, 1553–1566. [[CrossRef](#)] [[PubMed](#)]
184. Tohidpour, A. CagA-mediated pathogenesis of *Helicobacter pylori*. *Microb. Pathogen.* **2016**, *93*, 44–55. [[CrossRef](#)] [[PubMed](#)]
185. Tertti, R.; Skurnik, M.; Vartio, T.; Kuusela, P. Adhesion protein YadA of *Yersinia* species mediates binding of bacteria to fibronectin. *Infect. Immun.* **1992**, *60*, 3021–3024. [[PubMed](#)]
186. El Tahir, Y.; Skurnik, M. YadA, the multifaceted *Yersinia* adhesin. *Int. J. Med. Microbiol. IJMM* **2001**, *291*, 209–218. [[CrossRef](#)] [[PubMed](#)]
187. Isberg, R.R.; Leong, J.M. Multiple $\beta1$ chain integrins are receptors for invasins, a protein that promotes bacterial penetration into mammalian cells. *Cell* **1990**, *60*, 861–871. [[CrossRef](#)]
188. Hamzaoui, N.; Kerneis, S.; Caliot, E.; Pringault, E. Expression and distribution of $\beta1$ integrins in in vitro-induced M cells: implications for *Yersinia* adhesion to Peyer's patch epithelium. *Cell. Microbiol.* **2004**, *6*, 817–828. [[CrossRef](#)] [[PubMed](#)]
189. Schulte, R.; Kerneis, S.; Klinke, S.; Bartels, H.; Preger, S.; Kraehenbuhl, J.P.; Pringault, E.; Autenrieth, I.B. Translocation of *Yersinia enterocolitica* across reconstituted intestinal epithelial monolayers is triggered by *Yersinia* invasins binding to $\beta1$ integrins apically expressed on M-like cells. *Cell. Microbiol.* **2000**, *2*, 173–185. [[CrossRef](#)] [[PubMed](#)]
190. Clark, M.A.; Hirst, B.H.; Jepson, M.A. M-cell surface $\beta1$ integrin expression and invasins-mediated targeting of *Yersinia pseudotuberculosis* to mouse Peyer's patch M cells. *Infect. Immun.* **1998**, *66*, 1237–1243. [[PubMed](#)]
191. Leong, J.M.; Morrissey, P.E.; Marra, A.; Isberg, R.R. An aspartate residue of the *Yersinia pseudotuberculosis* invasins protein that is critical for integrin binding. *EMBO J.* **1995**, *14*, 422–431. [[PubMed](#)]
192. Hamburger, Z.A.; Brown, M.S.; Isberg, R.R.; Bjorkman, P.J. Integrin-Binding Protein Crystal Structure of Invasin: A Bacterial Crystal Structure of Invasin: A Bacterial Integrin-Binding Protein. *Science* **1999**, *286*, 291–295. [[CrossRef](#)] [[PubMed](#)]

193. Del Valle, A.; Jones, B.F.; Harrison, L.M.; Chadderdon, R.C.; Cappello, M. Isolation and molecular cloning of a secreted hookworm platelet inhibitor from adult *Ancylostoma caninum*. *Mol. Biochem. Parasitol.* **2003**, *129*, 167–177. [[CrossRef](#)]
194. Chadderdon, R.C.; Cappello, M. The hookworm platelet inhibitor: Functional blockade of integrins GPIIb/IIIa (α IIb β 3) and GPIa/IIa (α 2 β 1) inhibits platelet aggregation and adhesion in vitro. *J. Infect. Dis.* **1999**, *179*, 1235–1241. [[CrossRef](#)] [[PubMed](#)]
195. Seymour, J.L.; Henzel, W.J.; Nevins, B.; Stults, J.T.; Lazarus, R.A. Decorsin. A potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor from the leech *Macrobdella decora*. *J. Biol. Chem.* **1990**, *265*, 10143–10147. [[PubMed](#)]
196. Zhang, Z.; Gao, L.; Shen, C.; Rong, M.; Yan, X.; Lai, R. A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands. *Int. J. Biochem. Cell. Biol.* **2014**, *54*, 83–88. [[CrossRef](#)] [[PubMed](#)]
197. Ma, D.; Xu, X.; An, S.; Liu, H.; Yang, X.; Andersen, J.F.; Wang, Y.; Tokumasu, F.; Ribeiro, J.M.; Francischetti, I.M.; et al. A novel family of RGD-containing disintegrins (Tablysin-15) from the salivary gland of the horsefly *Tabanus yao* targets α IIb β 3 or α V β 3 and inhibits platelet aggregation and angiogenesis. *Thromb. Haemost.* **2011**, *105*, 1032–1045. [[CrossRef](#)] [[PubMed](#)]
198. Karczewski, J.; Endris, R.; Connolly, T.M. Disagregin is a fibrinogen receptor antagonist lacking the Arg-Gly-Asp sequence from the tick, *Ornithodoros moubata*. *J. Biol. Chem.* **1994**, *269*, 6702–6708. [[PubMed](#)]
199. Tang, J.; Fang, Y.; Han, Y.; Bai, X.; Yan, X.; Zhang, Y.; Lai, R.; Zhang, Z. YY-39, a tick anti-thrombosis peptide containing RGD domain. *Peptides* **2015**, *68*, 99–104. [[CrossRef](#)] [[PubMed](#)]
200. Wang, X.; Coons, L.B.; Taylor, D.B.; Stevens, S.E., Jr.; Gartner, T.K. Variabilin, a novel RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick *Dermacentor variabilis*. *J. Biol. Chem.* **1996**, *271*, 17785–17790. [[CrossRef](#)] [[PubMed](#)]
201. Mortimer, L.; Moreau, F.; Cornick, S.; Chadee, K. The NLRP3 Inflammasome Is a Pathogen Sensor for Invasive *Entamoeba histolytica* via Activation of α 5 β 1 Integrin at the Macrophage-Amebae Intercellular Junction. *PLoS Pathog.* **2015**, *11*, e1004887. [[CrossRef](#)] [[PubMed](#)]
202. Muchowski, P.J.; Zhang, L.; Chang, E.R.; Soule, H.R.; Plow, E.F.; Moyle, M. Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18. *J. Biol. Chem.* **1994**, *269*, 26419–26423. [[CrossRef](#)] [[PubMed](#)]
203. Hou, Y.; Mortimer, L.; Chadee, K. *Entamoeba histolytica* cysteine proteinase 5 binds integrin on colonic cells and stimulates NF κ B-mediated pro-inflammatory responses. *J. Biol. Chem.* **2010**, *285*, 35497–35504. [[CrossRef](#)] [[PubMed](#)]
204. Cornick, S.; Moreau, F.; Chadee, K. *Entamoeba histolytica* Cysteine Proteinase 5 Evokes Mucin Exocytosis from Colonic Goblet Cells via α v β 3 Integrin. *PLoS Pathog.* **2016**, *12*, e1005579. [[CrossRef](#)] [[PubMed](#)]
205. Kucik, C.J.; Martin, G.L.; Sortor, B.V. Common intestinal parasites. *Am. Fam. Physician* **2004**, *69*, 1161–1168. [[PubMed](#)]
206. Gunther, J.; Shafir, S.; Bristow, B.; Sorvillo, F. Short report: Amebiasis-related mortality among United States residents, 1990–2007. *Am. J. Trop. Med. Hyg.* **2011**, *85*, 1038–1040. [[CrossRef](#)] [[PubMed](#)]
207. Sim, S.; Park, S.J.; Yong, T.S.; Im, K.I.; Shin, M.H. Involvement of β 2-integrin in ROS-mediated neutrophil apoptosis induced by *Entamoeba histolytica*. *Microbes Infect.* **2007**, *9*, 1368–1375. [[CrossRef](#)] [[PubMed](#)]
208. Pillai, D.R.; Kain, K.C. *Entamoeba histolytica*: Identification of a distinct β 2 integrin-like molecule with a potential role in cellular adherence. *Exp. Parasitol.* **2005**, *109*, 135–142. [[CrossRef](#)] [[PubMed](#)]
209. Sengupta, K.; Hernandez-Ramirez, V.I.; Rosales-Encina, J.L.; Mondragon, R.; Garibay-Cerdenares, O.L.; Flores-Robles, D.; Javier-Reyna, R.; Pertuz, S.; Talamas-Rohana, P. Physical, structural, and functional properties of the β 1 integrin-like fibronectin receptor (β 1EhFNR) in *Entamoeba histolytica*. *Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis.* **2009**, *9*, 962–970. [[CrossRef](#)] [[PubMed](#)]
210. Ma, D.; Francischetti, I.M.; Ribeiro, J.M.; Andersen, J.F. The structure of hookworm platelet inhibitor (HPI), a CAP superfamily member from *Ancylostoma caninum*. *Acta Crystallogr. Sect. F Struct. Biol. Commun.* **2015**, *71*, 643–649. [[CrossRef](#)] [[PubMed](#)]
211. Moyle, M.; Foster, D.L.; McGrath, D.E.; Brown, S.M.; Laroche, Y.; de Meutter, J.; Stanssens, P.; Bogowitz, C.A.; Fried, V.A.; Ely, J.A.; et al. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. *J. Biol. Chem.* **1994**, *269*, 10008–10015. [[PubMed](#)]
212. Assumpcao, T.C.F.; Ribeiro, J.M.C.; Francischetti, I.M.B. Disintegrins from hematophagous sources. *Toxins* **2012**, *4*, 296–322. [[CrossRef](#)] [[PubMed](#)]

213. Fremont, L. Biological effects of resveratrol. *Life Sci.* **2000**, *66*, 663–673. [[CrossRef](#)]
214. Tseng, S.H.; Lin, S.M.; Chen, J.C.; Su, Y.H.; Huang, H.Y.; Chen, C.K.; Lin, P.Y.; Chen, Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. *Clin. Cancer Res.* **2004**, *10*, 2190–2202. [[CrossRef](#)] [[PubMed](#)]
215. Varoni, E.M.; Lo Faro, A.F.; Sharifi-Rad, J.; Iriti, M. Anticancer Molecular Mechanisms of Resveratrol. *Front. Nutr.* **2016**, *3*, 82–83. [[CrossRef](#)] [[PubMed](#)]
216. Chin, Y.T.; Hsieh, M.T.; Yang, S.H.; Tsai, P.W.; Wang, S.H.; Wang, C.C.; Lee, Y.S.; Cheng, G.Y.; HuangFu, W.C.; London, D.; et al. Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. *Oncotarget* **2014**, *5*, 12891–12907. [[CrossRef](#)] [[PubMed](#)]
217. Buhmann, C.; Shayan, P.; Goel, A.; Shakibaei, M. Resveratrol Regulates Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. *Nutrients* **2017**, *9*, 1073. [[CrossRef](#)] [[PubMed](#)]
218. Hoffman, S.J.; Vasko-Moser, J.; Miller, W.H.; Lark, M.W.; Gowen, M.; Stroup, G. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. *J. Pharmacol. Exp. Therap.* **2002**, *302*, 205–211. [[CrossRef](#)]
219. Lin, H.Y.; Sun, M.; Tang, H.Y.; Lin, C.; Luidens, M.K.; Mousa, S.A.; Incerpi, S.; Drusano, G.L.; Davis, F.B.; Davis, P.J. L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. *Am. J. Physiol. Cell Physiol.* **2009**, *296*, C980–C991. [[CrossRef](#)] [[PubMed](#)]
220. Santulli, G. Angiopoietin-like proteins: A comprehensive look. *Front. Endocrinol.* **2014**, *5*, 1–6. [[CrossRef](#)] [[PubMed](#)]
221. Zhang, Y.; Hu, X.; Tian, R.; Wei, W.; Hu, W.; Chen, X.; Han, W.; Chen, H.; Gong, Y. Angiopoietin-related growth factor (AGF) supports adhesion, spreading, and migration of keratinocytes, fibroblasts, and endothelial cells through interaction with RGD-binding integrins. *Biochem. Biophys. Res. Commun.* **2006**, *347*, 100–108. [[CrossRef](#)] [[PubMed](#)]
222. Liu, J.; Gao, X.; Zhai, Y.; Shen, Q.; Sun, L.; Feng, C.; Rao, J.; Liu, H.; Zha, X.; Guo, M.; et al. A novel role of angiopoietin-like-3 associated with podocyte injury. *Pediatr. Res.* **2015**, *77*, 732–739. [[CrossRef](#)] [[PubMed](#)]
223. Yang, Z.; Mu, Z.; Dabovic, B.; Jurukovski, V.; Yu, D.; Sung, J.; Xiong, X.; Munger, J.S. Absence of integrin-mediated TGF β 1 activation in vivo recapitulates the phenotype of TGF β 1-null mice. *J. Cell Biol.* **2007**, *176*, 787–793. [[CrossRef](#)] [[PubMed](#)]
224. Wynn, T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. *J. Clin. Investig.* **2007**, *117*, 524–529. [[CrossRef](#)] [[PubMed](#)]
225. Katsumoto, T.R.; Violette, S.M.; Sheppard, D. Blocking TGF β via Inhibition of the α v β 6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. *Int. J. Rheumatol.* **2011**, *2011*, 208219. [[CrossRef](#)] [[PubMed](#)]
226. Munger, J.S.; Huang, X.; Kawakatsu, H.; Griffiths, M.J.; Dalton, S.L.; Wu, J.; Pittet, J.F.; Kaminski, N.; Garat, C.; Matthay, M.A.; et al. The integrin α v β 6 binds and activates latent TGF β 1: A mechanism for regulating pulmonary inflammation and fibrosis. *Cell* **1999**, *96*, 319–328. [[CrossRef](#)]
227. Puthawala, K.; Hadjiangelis, N.; Jacoby, S.C.; Bayongan, E.; Zhao, Z.; Yang, Z.; Devitt, M.L.; Horan, G.S.; Weinreb, P.H.; Lukashev, M.E.; et al. Inhibition of integrin α v β 6, an activator of latent transforming growth factor- β , prevents radiation-induced lung fibrosis. *Am. J. Respir. Crit. Care Med.* **2008**, *177*, 82–90. [[CrossRef](#)] [[PubMed](#)]
228. Horan, G.S.; Wood, S.; Ona, V.; Li, D.J.; Lukashev, M.E.; Weinreb, P.H.; Simon, K.J.; Hahm, K.; Allaire, N.E.; Rinaldi, N.J.; et al. Partial inhibition of integrin α v β 6 prevents pulmonary fibrosis without exacerbating inflammation. *Am. J. Respir. Crit. Care Med.* **2008**, *177*, 56–65. [[CrossRef](#)] [[PubMed](#)]
229. Sullivan, L.A.; Brekken, R.A. The VEGF family in cancer and antibody-based strategies for their inhibition. *mAbs* **2010**, *2*, 165–175. [[CrossRef](#)] [[PubMed](#)]
230. Jayson, G.C.; Hicklin, D.J.; Ellis, L.M. Antiangiogenic therapy—evolving view based on clinical trial results. *Nat. Rev. Clin. Oncol.* **2012**, *9*, 297–303. [[CrossRef](#)] [[PubMed](#)]
231. Vlahakis, N.E.; Young, B.A.; Atakilit, A.; Sheppard, D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin α 9 β 1. *J. Biol. Chem.* **2005**, *280*, 4544–4552. [[CrossRef](#)] [[PubMed](#)]

232. Temming, K.; Schiffelers, R.M.; Molema, G.; Kok, R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. *Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother.* **2005**, *8*, 381–402. [[CrossRef](#)] [[PubMed](#)]
233. Marelli, U.K.; Rechenmacher, F.; Sobahi, T.R.; Mas-Moruno, C.; Kessler, H. Tumor Targeting via Integrin Ligands. *Front. Oncol.* **2013**, *3*, 222. [[CrossRef](#)] [[PubMed](#)]
234. Garanger, E.; Boturyn, D.; Dumy, P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. *Anti-Cancer Agents Med. Chem.* **2007**, *7*, 552–558. [[CrossRef](#)]
235. Wen, A.M.; Steinmetz, N.F. Design of virus-based nanomaterials for medicine, biotechnology, and energy. *Chem. Soc. Rev.* **2016**, *45*, 4074–4126. [[CrossRef](#)] [[PubMed](#)]
236. Hovlid, M.L.; Steinmetz, N.F.; Laufer, B.; Lau, J.L.; Kuzelka, J.; Wang, Q.; Hyypia, T.; Nemerow, G.R.; Kessler, H.; Manchester, M.; et al. Guiding plant virus particles to integrin-displaying cells. *Nanoscale* **2012**, *4*, 3698–3705. [[CrossRef](#)] [[PubMed](#)]
237. Anderson, E.H.; Ruegsegger, M.A.; Murugesan, G.; Kottke-Marchant, K.; Marchant, R.E. Extracellular matrix-like surfactant polymers containing arginine-glycine-aspartic acid (RGD) peptides. *Macromol. Biosci.* **2004**, *4*, 766–775. [[CrossRef](#)] [[PubMed](#)]
238. Guo, C.X.; Ng, S.R.; Khoo, S.Y.; Zheng, X.; Chen, P.; Li, C.M. RGD-peptide functionalized graphene biomimetic live-cell sensor for real-time detection of nitric oxide molecules. *ACS Nano* **2012**, *6*, 6944–6951. [[CrossRef](#)] [[PubMed](#)]
239. Stephanopoulos, N.; Freeman, R.; North, H.A.; Sur, S.; Jeong, S.J.; Tantakitti, F.; Kessler, J.A.; Stupp, S.I. Bioactive DNA-peptide nanotubes enhance the differentiation of neural stem cells into neurons. *Nano Lett.* **2015**, *15*, 603–609. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).